
WHAT IS CLAIMED IS:

1. A method for ameliorating or treating a paramyxovirus virus infection comprising administering to a subject infected with the paramyxovirus virus an effective amount of a combination of Compound (A) and one or more of Compound (B), or a pharmaceutical acceptable salt of any of the foregoing, wherein:


the Compound (A) has the structure:



(A),

wherein:

R^1 is selected from the group consisting of H, an optionally substituted acyl, an




optionally substituted O-linked amino acid and ;

R^2 is chloro or azido;


R^3 is selected from the group consisting of OH, $-OC(=O)R^{A1}$ and an optionally substituted O-linked amino acid;

R^4 and R^5 are independently H or D;


R^6 and R^7 is independently absent, H,



,





and



;

R^{A1} is an optionally substituted C_{1-24} alkyl;

R^{A2} is independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted $-O-C_{1-24}$

alkyl, an optionally substituted –O–aryl, an optionally substituted –O–heteroaryl, an optionally substituted –O–monocyclic heterocyclyl,  and ;

R^{A3} is selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{C1} and R^{C2} are independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

s is 0, 1, 2 or 3;

t is 0 or 1; and


Z^1 is O or S;

one or more of Compound (B) is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing; and

the paramyxovirus virus infection is selected from the group consisting of a respiratory syncytial virus infection, a parainfluenza virus infection and a metapneumovirus infection.



2. A method for ameliorating or treating a paramyxovirus virus infection comprising contacting a cell infected with the paramyxovirus virus with an effective amount of a combination of Compound (A) and one or more of Compound (B) , or a pharmaceutical acceptable salt of any of the foregoing, wherein:

the Compound (A) has the structure:



(A),




wherein:

R^1 is selected from the group consisting of H, an optionally substituted acyl, an optionally substituted O-linked amino acid,  and ;

R^2 is chloro or azido;



R^3 is selected from the group consisting of OH, $-OC(=O)R^{A1}$ and an optionally substituted O-linked amino acid;

R^4 and R^5 are independently H or D;

R^6 and R^7 is independently absent, H, ,  and ;

R^8, R^9 and each R^{10} are independently absent or H;

R^{A1} is an optionally substituted C_{1-24} alkyl;

R^{A2} is independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted $-O-C_{1-24}$ alkyl, an optionally substituted –O–aryl, an optionally substituted –O–heteroaryl, an optionally substituted –O–monocyclic heterocyclyl,  and ;

R^{A3} is selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{C1} and R^{C2} are independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

m is 1 or 2;

s is 0, 1, 2 or 3;

t is 0 or 1; and


Z^1 is O or S;

one or more of Compound (B) is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing; and

the paramyxovirus virus infection is selected from the group consisting of a respiratory syncytial virus infection, a parainfluenza virus infection and a metapneumovirus infection.



3. Use of an effective amount of a combination of Compound (A) and one or more of Compound (B), or a pharmaceutical acceptable salt of any of the foregoing, in the preparation of a medicament for ameliorating or treating a paramyxovirus virus infection wherein:

the Compound (A) has the structure:



(A),




wherein:

R^1 is selected from the group consisting of H, an optionally substituted acyl, an optionally substituted O-linked amino acid,  and ;

R^2 is chloro or azido;



R^3 is selected from the group consisting of OH, $-OC(=O)R^{A1}$ and an optionally substituted O-linked amino acid;

R^4 and R^5 are independently H or D;

R^6 and R^7 is independently absent, H, ,  and ;

R^8, R^9 and each R^{10} are independently absent or H;

R^{A1} is an optionally substituted C_{1-24} alkyl;

R^{A2} is independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl, an optionally substituted –O–aryl, an optionally substituted –O–heteroaryl, an optionally substituted –O–monocyclic heterocyclyl,  and ;

R^{A3} is selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{C1} and R^{C2} are independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

m is 1 or 2;

s is 0, 1, 2 or 3;

t is 0 or 1; and

Z^1 is O or S;

one or more of Compound (B) is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing; and

the paramyxovirus virus infection is selected from the group consisting of a respiratory syncytial virus infection, a parainfluenza virus infection and a metapneumovirus infection.

4. The method or use of any one of Claims 1-3, wherein the paramyxovirus virus infection is a respiratory syncytial virus infection.

5. The method or use of Claim 4, wherein the RSV is Type A.

6. The method or use of Claim 4, wherein the RSV is Type B.

7. The method or use of any one of Claims 1-3, wherein the paramyxovirus virus infection is a parainfluenza virus infection.

8. The method or use of any one of Claims 1-3, wherein the paramyxovirus virus infection is a metapneumovirus infection.

9. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is an anti-RSV antibody.

10. The method or use of Claim 9, wherein the anti-RSV antibody is selected from the group consisting of

RSV-IGIV (RespiGam®)

palivizumab (Synagis®, a chimeric humanized IgG monoclonal antibody) and

motavizumab (MEDI-524, humanized monoclonal antibody).

11. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is a fusion protein inhibitor.

12. The method or use of Claim 11, wherein the fusion protein inhibitor is selected from the group consisting of

1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one (BMS-433771),

4,4"-bis-{4,6-bis-[3-(bis-carbamoylmethyl-sulfamoyl)-phenylamino]-(1,3,5)triazin-2-ylamino}-biphenyl-2,2"-disulfonic-acid (RFI-641),

4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazine-2-ylamino]-biphenyl-2,2'-disulfonic acid, disodium salt (CL387626),

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]-6-methyl-3-pyridinol (JNJ-2408068),

2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol (TMC-353121),

5,5′-bis[1-(((5-amino-1H-tetrazolyl)imino)methyl)]2,2′,4″-methylidynetrisphenol (VP-14637, MDT-637),

N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide (P13),

2-((2-((1-(2-aminoethyl)piperidin-4-yl)amino)-4-methyl-1H-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol (R170591),

1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane (C15),

(R)-9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydro-1H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5(9bH)-one (BTA9981),

[2,2-bis(docosyloxy-oxymethyl)propyl-5-acetaoamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium-oxysulfonyl)-D-glycero-D-galacto-2-nonulopyranosid]onate (MBX-300),

BTA-C286,

N-(2-((S)-2-(5-((S)-3-aminopyrrolidin-1-yl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)-4-chlorophenyl)methanesulfonamide (GS-5806),

an anti-RSV nanobody and

a peptide fusion inhibitor,

or a pharmaceutically acceptable salt of any of the foregoing.

13. The method or use of Claim 12, wherein peptide fusion inhibitor is selected from the group consisting of:

a peptide having the sequence DEFDASISQVNEKINQSLAFIRKSDELL (T-67), and

a peptide having the sequence FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST (T-118).

14. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is an N-protein inhibitor.

15. The method or use of Claim 14, wherein the N-protein inhibitor is selected from the group consisting of (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (RSV-604), STP-92 (siRNA delivered through nanoparticle based delivery system, Sirnaomics) and iKT-041 (Inhibikase), or a pharmaceutically acceptable salt thereof.

16. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is a RSV polymerase inhibitor.

17. The method or use of Claim 16, wherein the RSV polymerase inhibitor is selected from the group consisting of

6-{4-[(biphenyl-2-ylcarbonyl)amino]benzoyl}-N-cyclopropyl-5,6-dihydro-4H-thieno[3,2-d][1]benzazepine-2-carboxamide (YM-53403),

N-cyclopropyl-5-(4-(2-(pyrrolidin-1-yl)benzamido)benzoyl)-5,6,7,10-tetrahydrobenzo[b]cyclopenta[d]azepine-9-carboxamide,

6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide,

4-amino-8-(3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl)-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-1H-imidazo[4,5-h]-isoquinoline-7,9(6H,8H)-dione and

6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide (AZ27),

or a pharmaceutically acceptable salt of any of the foregoing.

18. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is an IMPDH inhibitor.

19. The method or use of Claim 18, wherein the IMPDH inhibitor is selected from the group consisting of

ribavirin,

5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR),

4-hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide (pyrazofurin),

1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide (Taribavirin, viramidine),

1,3,4-thiadiazol-2-ylcyanamide (LY253963),

tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (VX-497),

(4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid (Mycophenolic acid) and

2-morpholin-4-ylethyl-(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate (Mycophenolate Mofetil),

or a pharmaceutically acceptable salt of any of the foregoing.

20. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is an interferon.

21. The method or use of Claim 20, wherein the interferon is a pegylated interferon.

22. The method or use of any one of Claims 20-21, wherein the interferon is a Type 1 interferon.

23. The method or use of Claim 22, wherein the Type 1 interferon is an alpha-interferon (IFN-α).

24. The method or use of Claim 23, wherein the IFN-α is selected from the group consisting of Pegylated interferon-alpha-2a (PEGASYS®), Pegylated interferon-alpha-2b (PEG-INTRON®) and interferon alfacon-1 (INFERGEN®).

25. The method or use of any one of Claims 20-21, wherein the Type 1 interferon is a beta-interferon (IFN-β).

26. The method or use of any one of Claims 20-21, wherein the interferon is a Type 2 interferon.

27. The method or use of any one of Claims 20-21, wherein the interferon is a Type 3 interferon.

28. The method or use of Claim 27, wherein the Type 3 interferon is a lambda-interferon (IFN-λ).

29. The method or use of Claim 28, wherein the IFN-λ is pegylated interferon lambda.

30. The method or use of any one of Claims 1-8, wherein one or more of Compound (B) is an other compound that inhibits the RSV virus.

31. The method or use of Claim 30, wherein the other compound is selected from the group consisting of

a double stranded RNA oligonucleotide,

5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide (leflumomide),

N-(2-chloro-4-methylphenyl)-2-((1-(4-methoxyphenyl)-1H-benzo[d]imidazol-2-yl)thio)propanamide (JMN3-003),

Medi-559,

Medi-534,

Medi-557,

an intratracheal formulation of recombinant human CC10 (CG-100),


high titer, human immunoglobulin (RI-001, ADMA Biologics Inc.) and

a non-neutralizing mAb against the G protein (mAb 131-2G),

or a pharmaceutically acceptable salt of any of the foregoing.


32. The method or use of Claim 31, wherein the double stranded RNA oligonucleotide is ALN-RSV01 or ALN-RSV02.

33. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B1) having the structure:




or a stereoisomeric form thereof, wherein


Het is a heterocycle having formula (b), (c), (d) or (e)




(b)



(c)



(d)



(e)

each X independently is C or N; provided that at least one X is N;

R^{1b} is present when Het has formula (b) and X is C; each R^{1b} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1b} is absent when the X to which it is bound is N;

R^{2b} is $-(CR^8R^9)_m-R^{10b}$;

each R^6 is independently selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$ and $CONHSO_2CH_3$;

each R^7 is independently selected from the group consisting of OH, C_1-C_6 alkyloxy, NH_2, $NHSO_2N(C_1$-C_6 alkyl$)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl) and $N(C_1$-C_6 alkyl$)_2$;

each R^8 and R^9 are independently chosen from the group consisting of H, C_1-C_{10} alkyl and C_3-C_7 cycloalkyl; or R^8 and R^9 taken together form a 4 to 6 membered aliphatic ring that optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10b} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, O-Benzyl, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$, and a 4 to 6 membered saturated ring containing one oxygen atom;

m is an integer from 2 to 6;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{12} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{12} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{1c} is present when Het has formula (c);

each R^{1c} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^{7c})$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O$-C_1-C_6 alkyl$)_2$;

R^{3c} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy and $CO(R^{7c})$;

R^{2c} is $-(CR^8R^9)_m$-R^{10c};

R^{7c} is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl$)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), $N(C_1$-C_6 alkyl$)_2$, NR^8R^9 and NR^9R^{10c};

R^{10c} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9,

NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{1d} is present when Het has formula (d) and X is C; each R^{1d} is selected independently from the group consisting of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1d} is absent when the X to which it is bound is N;

R^{3d} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, and $CO(R^7)$;

R^{2d} is $-(CR^8R^9)_m\text{-}R^{10d}$;

R^{10d} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR_9, $OCOR^8$,$NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

each Y independently is C or N;

R^{1e} is present when Het has formula (e) and Y is C; each R^{1e} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1e} is absent when the Y to which it is bound is N;

R^{3e} is selected from the group consisting of H, halogen, $-(CR^8R^9)_m\text{-}R^{10e}$, $C\equiv C\text{-}CH_2\text{-}R^{10e}$, $C\equiv C\text{-}R^{10e}$ and $C=CR^{10e}$;

R^{10e} is selected from the group consisting of H, R^{11}, C_1-C_6 alkyloxy, OH, CN, F, CF_2H,CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^4 is selected from the group consisting of tert-butyl, Het^1, aryl, Het^2, $CH(CH_3)(CF_3)$, and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo C_1-C_4 alkyloxy, C_1-C_4 alkyl, OH, CN, CF_2H, CF_3, CF_30, $CONR^8R^9$, $COOR^8$,$CON(R^8)SO_2R^9$,

$CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$,$SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$; or C_1-C_4 alkyloxyC_1-C_4 alkyloxy;

Het^1 represents a 4 to 6 membered saturated ring containing one N atom, optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^8 , C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy; or


Het^1 represents a 4 to 6 membered saturated ring containing one O atom, substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, CF_3, $NH(C=O)(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl) and C_1-C_4 alkyl; or Het represents a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N, optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^8, C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;

Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, C_1-C_4 alkyl, OH, CN, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONRV^2$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$;

Z is C or N; R^5 is present where Z is C, whereby R^5 is selected form the group consisting of hydrogen, CF_3 and halogen; R^5 is absent where Z is N;


or a pharmaceutically acceptable addition salt or a solvate thereof.

34. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B2) having the structure:



a tautomer or a stereoisomeric form thereof, wherein

Het is a heterocycle having formula (a)



R^{1a} is Br or Cl;

R^{2a} is $-(CR^{8a}R^{9a})_n-R^{10a}$;

each R^{8a} and R^{9a} are independently chosen from the group consisting of H, C_1-C_{10} alkyl and C_3-C_7 cycloalkyl; or R^{8a} and R^{9a} taken together form a 4 to 6 membered aliphatic ring; wherein the 4 to 6 membered aliphatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10a} is selected from the group consisting of H, C_1-C_6 alkyl, R^{11}, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR^{8a}SO_2R^{8a}$, $SO_2NR^{8a}R^{9a}$, $NR^{8a}SO_2C_3$-C_7 cycloalkyl, CN, $NR^{8a}R^{9a}$, COOH, $COOR^{8a}$, $CONR^{8a}R^{9a}$, $OCOC_1$-C_6 alkyl, $CONR^{8a}SO_2R^{9a}$, $CONR^{8a}SO_2NR^{8a}R^{9a}$, a 4 to 6 membered aliphatic ring and a 5 to 6 membered aromatic ring; wherein the aliphatic or aromatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

n is an integer having a value from 1 to 6;

R^5 is selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkyloxy, CN, CF_3 and halo;

R^4 is selected from the group consisting of hydrogen, tert-butyl, C_3-C_7 cycloalkyl, $CH(CH_3)(CF_3)$, C_2-C_{10} alkenyl, CH_2CF_3, SO_2CH_3, $-CH_2$-p-fluorophenyl, aryl, Het^1, Het^2 and

C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11a}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11a}$, and C_1-C_4 alkyl;

Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^{8a} C_1-C_4 alkylcarbonyl, C_1-C_4 alkyloxycarbonyl, CO(aryl), $COHet^2$, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $NH(C{=}O)(C_1$-C_4 alkyl), $(C{=}O)NH(C_1$-C_4 alkyl), $(C{=}S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;


Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$,$NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11a}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11a}$ and C_1-C_4 alkyl;

R^{11a} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{11a} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

Z is CH or N;


or a pharmaceutically acceptable addition salt or a solvate thereof.

35. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B3) having the structure:




a tautomer or a stereoisomeric form thereof, wherein


Het is a heterocycle having formula (b), (c), (d) or (e)




(b)



(c)



(d)



(e)

each X independently is C or N; provided that at least one X is N;

R^{1b} is present when Het has formula (b) and X is C; each R^{1b} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $C(O)(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$; R^{1b} is absent when the X to which it is bound is N;

R^{2b} is $-(CR^8R^9)_m\text{-}R^{10b}$;

each R^6 is independently selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$ and $CONHSO_2CH_3$; each R^7 is independently selected from the group consisting of OH, C_1-C_6 alkyloxy, NH_2, $NHSO_2N(C_1\text{-}C_6$ alkyl$)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1\text{-}C_6$ alkyl), $NHSO_2(C_3\text{-}C_7$ cycloalkyl) and $N(C_1\text{-}C_6\text{-}$alkyl$)_2$;

each R^8 and R^9 are independently chosen from the group consisting of H, C_1-C_6 alkyl and C_3-C_7 cycloalkyl; or R^8 and R^9 taken together form a 4 to 6 membered aliphatic ring that

optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10b} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, O-Benzyl, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$ and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{12} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

or R^{12} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

m is an integer from 2 to 6;

R^{1c} is present when Het has formula (c);

each R^{1c} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^{7c})$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6alkyl)_2$;

R^{3c} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy and $CO(R^{7c})$;

R^{2c} is $-(CR^8R^9)_m\text{-}R^{10c}$;

R^{7c} is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), $N(C_1$-C_6-alkyl)$_2$, NR^8R^9 and NR^9R^{10c};

R^{10c} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{1d} is present when Het has formula (d) and X is C; each R^{1d} is selected independently from the group consisting of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl,

C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\ alkyl)_2$; R^{1d} is absent when the X to which it is bound is N;

R^{3d} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, and $CO(R^7)$;

R^{2d} is $-(CR^8R^9)_m\text{-}R^{10d}$;

R^{10d} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

each Y independently is C or N;

R^{1e} is present when Het has formula (e) and Y is C; each R^{1e} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\ alkyl)_2$; R^{1e} is absent when the Y to which it is bound is N;

R^{3e} is selected from the group consisting of H, halogen, $-(CR^8R^9)_m\text{-}R^{10e}$, $C\equiv C\text{-}CH_2\text{-}R^{10e}$, $C\equiv C\text{-}R^{10e}$ and $C=C\text{-}R^{10e}$;

R^{10e} is selected from the group consisting of H, R^{11}, C_1-C_6 alkyloxy, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^5 is selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkyloxy, CN, CF_3 and halogen;

R^4 is selected from the group consisting of hydrogen, C_3-C_7 cycloalkyl, tert-butyl, C_2-C_{10} alkenyl, CH_2CF_3, $CH(CH_3)(CF_3)$, SO_2CH_3, $-CH_2$-p-fluorophenyl, aryl, Het^1, Het^2 and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4alkyloxy, C_1-C_4alkyl, OH, CN, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$,

$CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$ and $N(R^8)COOR^{12}$;


Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R, C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl),$NH(C=O)(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl) and C_1-C_4 alkyl;

Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, C_1-C_4 alkyl, OH, CN, CF_2H, CF_3, CONRV, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$ and $N(R^8)COOR^{12}$;

Z is CH or N;


or a pharmaceutically acceptable addition salt or a solvate thereof.

36. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B4) having the structure:



or a stereoisomeric form thereof, wherein

Het is a heterocycle having formula (a)


(a)

R^{1a} is Br or Cl;

R^{2a} is $-(CR^{8a}R^{9a})_n-R^{10a}$;

each R^{8a} and R^{9a} are independently chosen from the group consisting of H, C_1-C_{10} alkyl and C_3-C_7 cycloalkyl; or R^{8a} and R^{9a} taken together form a 4 to 6 membered aliphatic ring; wherein the 4 to 6 membered aliphatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10a} is selected from the group consisting of H, C_1-C_6 alkyl, R^{11}, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR^{8a}SO_2R^{8a}$, $SO_2NR^{8a}R^{9a}$, $NR^{8a}SO_2C_3$-C_7 cycloalkyl, CN, $NR^{8a}R^{9a}$, COOH, $COOR^{8a}$, $CONR^{8a}R^{9a}$, $OCOC_1$-C_6 alkyl, $CONR^{8a}SO_2R^{9a}$, $CONR^{8a}SO_2NR^{8a}R^{9a}$, a 4 to 6 membered aliphatic ring and a 5 to 6 membered aromatic ring; wherein the aliphatic or aromatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

n is an integer having a value from 1 to 6;

R^4 is selected from the group consisting of tert-butyl, $CH(CH_3)(CF_3)$, aryl, Het^1, Het^2 and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl; aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11b}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11b}$, and C_1-C_4 alkyl;

Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 11 non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being

substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^{8a} C_1-C_4 alkylcarbonyl, C_1-C_4 alkyloxycarbonyl, CO(aryl), $COHet^2$, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl)$_2$, $SO_2NH(C_1$-C_4 alkyl), $NH(C=O)(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;


Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF$_2$H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11b}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11b}$ and C_1-C_4 alkyl;

R^{11b} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{11b} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

Z is C or N; R^5 is present where Z is C, whereby R^5 is selected from the group consisting of hydrogen, CF_3 and halogen; R^5 is absent where Z is N;

or a pharmaceutically acceptable addition salt or a solvate thereof.

37. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B5) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_6)_2$, $CO(R_7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$;

R_2 is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, and $CO(R_7)$;

R_3 is $-(CR_8R_9)_n\text{-}R_{10}$;

R_4 is selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, $SO_2\text{-}R_8$, CH_2CF_3, SO_2CH_3 or a 4 to 6 membered saturated ring containing an oxygen atom;

R_5 is present where X is C, and is selected from the group consisting of H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen; R_5 is absent where X is N;

R_6 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;


R_7 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl$)_2$, $NHSO_2NCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6 alkyl$)_2$, NR_8R_9, NR_9R_{10};

n is an integer from 2 to 6;

R_8 and R_9 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_8 and R_9 taken together form a 4 to 6 membered aliphatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

R_{10} is selected from the group consisting of H, C_1-C_6 alkyl, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR_8R_9$, $COOR_8$, $CONR_8SO_2R_9$, $CON(R_8)SO_2N(R_8R_9)$, NR_8R_9, NR_8COOR_9, $OCOR_8$, $NR_8SO_2R_9$, $SO_2NR_8R_9$, SO_2NR_8 or a 4 to 6 membered saturated ring containing an oxygen atom.

38. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B6) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N; at least one X = N;

each Y independently is C or N;

R_1 is present when X = C and R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_5)_2$, $CO(R_6)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6\ alkyl)_2$; R_1 is absent when X = N;

R_2 is $-(CR_7R_8)_n\text{-}R_9$;

R_3 is selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, $SO_2\text{-}R_7$, CH_2CF_3 or a 4 to 6 membered saturated ring containing an oxygen atom;

R_4 is present where Y is C and is selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, $COO(R_7)$, CF_3 and halogen,

R_5 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;

R_6 is selected from the group consisting of OH, $O(C_1\text{-}C_6\ alkyl)$, NH_2, $NHSO_2N(C_1\text{-}C_6\ alkyl)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1\text{-}C_6\ alkyl)$, $NHSO_2(C_3\text{-}C_7\ cycloalkyl)$, and $N(C_1\text{-}C_6\text{-}alkyl)_2$;


R_7 and R_8 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_7 and R_8 taken together form a 4 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group N, S, O;

R_9 is selected from the group consisting of H, R_{10}, C_1-C_6 alkyl, OH, CN, F, CF_2H, CF_3, $CONR_7R_8$, $COOR_7$, $CON(R_7)SO_2R_8$, $CON(R_7)SO_2N(R_7R_8)$, NR_7R_8, NR_7COOR_8, $OCOR_7$, O-Benzyl, $NR_7SO_2R_8$, SO_2 R_7R_8, SO_2R_7, $OCONR_7R_8$, $OCONR_7R_{10}$, $N(R_7)CON(R_7R_8)$, $N(R_7)COOC$; phtalimido, 2-methyl-benzothiophene(1,1)di oxide, or a 4 to 6 membered saturated ring containing an oxygen atom;

n is an integer from 2 to 6;

R_{10} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl , phenyl, pyridine or pyrazole, optionally substituted with one or more substituents selected from the group comprising CF_3, CH_3, OCH_3, OCF_3 or halogen.

39. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B7) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N with at least one X being N;

R_1 is present where X = C and R_1 selected from the group of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, NH_2, $CO(R_7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$;

R_2 is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, and $CO(R_7)$;

R_3 is $-(CR_8R_9)_n\text{-}R_{10}$;

R_4 is selected from the group consisting of H, C_1-C_{10} alkyl, CH_2CF_3 C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, SO_2-R_8, or a 4 to 6 membered saturated ring containing an oxygen atom;

R_5 is present where Y is C, and is selected from the group consisting of H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen;

R_5 is absent where X is N;

R_6 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;


R_7 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$,N HSO_2NHCH_3, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6-alkyl)$_2$;

n is an integer from 2 to 6;

R_8 and R_9 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_8 and R_9 taken together form a 4 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group N, S, O;

R_{10} is selected from the group consisting of H, C_1-C_6 alkyl, OH, CN, F, CF_2H, CF_3, $CONR_8R_9$, $COOR_8$, $CONR_8SO_2R_9$, $CON(R_8)SO_2N(R_8R_9)$, NR_8R_9, NR_8COOR_9, $OCOR_8$, $NR_8SO_2R_9$, $SO_2NR_8R_9$, SO_2R_8 or a 4 to 6 membered saturated ring containing an oxygen atom.

40. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B8) having the structure:



or a prodrug, N oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

each Y independently is C or N;

R_1 is present when X = C and R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_5)_2$, $CO(R_6)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O$-C_1-C_6 alkyl)$_2$; R_1 is absent when X = N

R_2 is selected from the group consisting of H, halogen, $-(CR_7R_8)_n$-R_9, $C\equiv C$-CH_2-R_9 and $C\equiv C$-R_9, $C=C$-R_9;

R_3 is selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, SO_2-R_7, or a 4 to 6 membered saturated ring containing an oxygen atom;

R_4 is present where Y is C and is selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen,

R_5 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;


R_6 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6-alkyl)$_2$;

R_7 and R_8 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_7 and R_8 taken together form a 4 to 6 membered aliphatic ring that optionally contains at least one heteroatom selected from the group N, S, O;

R_9 is selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl OH, CN, F, CF_2H, CF_3, $CONR_7R_8$, $COOR_7$, $CON(R_7)SO_2R_8$, $CON(R_7)SO_2N(R_7R_8)$, NR_7R_8, NR_7COOR_8, $OCOR_7$, $NR_7SO_2R_8$, $SO_2NR_7R_8$, SO_2R_7 or a 4 to 6 membered saturated ring containing an oxygen atom;

n is an integer from 2 to 6.

41. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B9) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

R_1 is H;

R_2 is selected from the group consisting of Br and Cl;

R_3 is $-(CR_6R_7)_n-R_8$;

R_4 is selected from the group consisting of H, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, -$(CR_6R_7)_n$-R_8, -CH_2-p-Fluorophenyl, CH_2CF_3 and -SO_2CH_3;


R_5 is present where X is C, whereby each R_5 is selected, each independently, from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, and CN; R_5 is absent where X is N;

R_6 and R_7 are each independently chosen from H and C_1-C_{10} alkyl, C_3-C_7 cycloalkyl; or R_6 and R_7 taken together form a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

R_8 is selected from the group consisting of H, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR_6SO_2R_6$, $SO_2R_6R_7$, $R_6SO_2C_3$-C_7 cycloalkyl, CN, NR_6R_7, COOH, $COOR_6$, $CONR_6R_7$, $OCOC_1$-C_6 alkyl, $CONR_6SOR_7$, CONH-R_6-SO_2R_7 , CONH-R_6-$SO_2NR_6R_7CONR_6SO_2NR_6R_7$, phtalimido or a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

n is an integer having a value from 1 to 6.

42. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B10) having the structure:



wherein

R^1, $R^3$and R^4 each independently represents H, C1-6 alkyl or halogen;

R^2 represents H, CN, CH_2NH_2, $CH_2NH(CH_2)_3NH_2$, C(=NH)NH_2 or C(=NOH)NH_2;


R^5 represents C1-6 alkyl; said C1-6 alkyl being optionally substituted with one or more of OR^{13}, CF_3, CN or $NR^{14}R^{15}$ wherein R^{13} represents H or C1-6 alkyl and R^{14} and R^{15} independently represent H, C1-6 alkyl or C3-7 cycloalkyl; or the group -$NR^{14}R^{15}$ together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR^{19} wherein R^{19} represents H or C1-6 alkyl;

R^6, R^7, R^8 and R^9 each independently represents CH, C-F, C-Cl, C-CF_3 or N;

R^{10} represents aryl, heteroaryl, C3-7 cycloalkyl or C1-6 alkyl; said C1-6 alkyl or C3-7 cycloalkyl being optionally substituted with one or more of aryl, C3-7 cycloalkyl, OR^{16}, SR^{16}, halogen or $NR^{17}R^{18}$, wherein R^{16} represents H or C1-6 alkyl and R^{17} and R^{18} each independently represents H, C1-6 alkyl or C3-7 cycloalkyl; or the group $-NR^{17}R^{18}$ together represents a 5 to 7 membered azacyclic ring optionally incorporating one heteroatom selected from O, S and NR^{20} wherein R^{20} represents H or C1-6 alkyl; and

R^{11} and R^{12} each independently represents H or C1-6 alkyl.

43. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B11) having the structure:



or racemates, isomers and/or salts thereof,

wherein:


X_1 and X_2 are independently selected from CH and N wherein at least one of X_1 and X_2 is N;

R_1 is optionally substituted and is selected from a carbocyclic, heterocyclic and aromatic ring;

R_2 is selected from C_{1-6} alkyl, haloC_{1-3}alkyl and C_{1-3}alkoxy; and

R_3 is H or an optional substituent.

44. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B12) having the structure:



or an enantiomer or a salt thereof,

wherein:

R^1 is -(CH=CH)$_{0-1}$-(C_6 or C_{10})aryl or -(CH=CH)$_{0-1}$-5-, 6-, 9- or 10- membered heteroaryl, said aryl or heteroaryl being optionally substituted with one, two or three substituents, each independently selected from: (C_{1-6})alkyl optionally substituted with amino, halo, (C_{1-6})haloalkyl, hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, nitro, azido, cyano, amino,(C_{1-6})alkylamino, di((C_{1-6})alkyl)amino, aryl and heteroaryl;


R^2 is H, (C_{1-6})alkyl, hydroxy, halo, (C_{1-6})haloalkyl, amino, (C_{1-6})alkylamino. di((C_{1-6})alkyl)amino, or (C_{2-6})alkynyl;

R^3 is (C_6, C_{10} or C_{14})aryl or 5-, 6-, 9- or 10-membered heteroaryl, each of which being optionally substituted with one, two or three substituents, each independently selected from: (C_{1-6})alkyl, halo, (C_{1-6})haloalkyl, hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, nitro, amino, (C_{1-6})alkylamino, di((C_{1-6})alkyl)amino and COO(C_{1-6})alkyl; and

R^4 and R^5 are each independently H or (C_{1-6})alkyl; or R^4 and R^5 are linked, together with the carbon atom to which they are attached, to form a (C_{3-7})cycloalkyl group;

with the proviso that R^1 is not 2-methoxyphenyl, when R^2 is H, R^3 is 3,4-dimethoxyphenyl, R^4 is CH_3 and R^5 is CH_3.


45. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B13) having the structure:



or a salt or a stereochemically isomeric form thereof,

wherein:

R is a radical of formula



(a) (b)

Q is hydrogen or C_{1-6}alkyl optionally substituted with a heterocycle or Q is C_{1-6}alkyl substituted with both a radical -OR^4 and a heterocycle; wherein said heterocycle is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl,1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, hydroxy, carboxyl, C_{1-6} alkyloxycarbonyl, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, C_{1-6}alkylcarbonylamino, aminosulfonyl and mono- or di(C_{1-6}alkyl)aminosulfonyl;

Alk is C_{1-6}alkanediyl;

X is O or S;

-a^1=a^2-a^3=a^4- is a bivalent radical of formula -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- or -CH=CH-CH=N-; wherein one of the nitrogen atoms bears the chemical bond linking radical (b) with the rest of the molecule;

R^1 is Ar or a heterocycle selected from pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, pyridopyridyl, naphthiridinyl, lH-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]- pyridinyl, imidazo[1,2-a]pyridinyl and 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; wherein each of said heterocycle may optionally be substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyloxy, (C_{1-6}alkyl-oxy)C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkyloxycarbonyl, aminocarbonyl, mono- and di- C_{1-6}alkylaminocarbonyl;

R^2 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, Ar-C_{1-6}alkyloxy-C_{1-6}alkyl, C_{3-7} cycloalkyl, cyano-C_{1-6}alkyl, Ar-C_{1-6}alkyl, Het-C_{1-6}alkyl;


R^3 is hydrogen, C_{1-6}alkyl, cyano, aminocarbonyl, polyhaloC_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

R^4 is hydrogen or C_{1-6}alkyl;

each Ar independently is phenyl or phenyl substituted with 1 to 5, such as 1, 2, 3 or 4, substituents selected from halo, hydroxy, amino, mono- or di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino, cyano, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, phenyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkyloxy, polyhaloC_{1-6}alkyloxy, phenoxy, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, hydroxycarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylcarbonyl, amino sulfonyl, mono- and di(C_{1-6}alkyl)- aminosulfonyl;

Het is a heterocycle selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, iuranyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl and 2,3-dihydro-1,4-dioxino-[2,3-b]pyridyl; wherein each Het may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, amino, mono- or di(C_{1-6}alkyl)amino, cyano, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkyloxy.

46. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B14) having the structure:




or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

G is a direct bond or C_{1-10}alkanediyl optionally substituted with one or more substituents independently selected from the group of substituents consisting of hydroxy, C_{1-6}alkyloxy, Ar^1 C_{1-6}alkyloxy,C_{1-6}alkylthio, Ar^1 C_{1-6}alkylthio,$HO(-CH_2-CH_2-O)_n$-, C_{1-6}alkyloxy$(-CH_2-CH_2-O)_n$- or Ar^1 C_{1-6}alkyloxy$(-CH_2-CH_2-O)$n-;

each n independently is 1, 2, 3 or 4;

R^1 is Ar^1 or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro- furanyl, thienyl, pynolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]- pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl or a radical of formula



;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted with 1 or where possible more, such as 2, 3, 4 or 5, substituents independently selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyCi-ealkyl, Ar^1, Ar^1C_{1-6}alkyl, Ar^1C_{1-6}alkyloxy, hydroxyC_{1-6}alkyl,mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino,C_{1-6}alkyl-SO_2-NR^{5c}-, Ar^1-SO_2-NR^{5c}-, C_{1-6}alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-CH_2-CH_2-O)$_n$-, halo(-CH_2-CH_2-O)$_n$-, C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$-, Ar^1C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$- and mono-or di(C_{1-6}alkyl)amino(-CH_2-CH_2-O)$_n$-;

each m independently is 1 or 2;

each p independently is 1 or 2;

each t independently is 0, 1 or 2;

Q is hydrogen, amino or mono- or di(C_{1-4}alkyl)amino;

one of R^{2a} and R^{3a} is selected from halo, optionally mono- or polysubstituted C_{1-6}alkyl, optionally mono- or polysubstituted C_{2-6}alkenyl, nitro, hydroxy, Ar^2, $N(R^{4a}R^4)$, $N(R^{4a}R^{4b})$sulfonyl, $N(R^{4a}R^4)$carbonyl, C_{1-6}alkyloxy, Ar^2oxy, Ar^2C_{1-6}alkyloxy,carboxyl, C_{1-6}alkyloxycarbonyl, or $-C(=Z)Ar^2$; and the other one of R^{2a} and R^{3a} is hydrogen; wherein =Z is =O, =CH-C(=O) $-NR^{5a}R^{5b}$, $=CH_2$, =CH- C_{1-6}alkyl, =N-OH or =N-O- C_{1-6}alkyl; and the optional substituents on C_{1-6}alkyl and C_{2-6} alkenyl can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydroxy, cyano, halo, nitro, $N(R^{4a}R^{4b})$, $N(R^{4a}R^{4b})$sulfonyl, Het, Ar^2, C_{1-6}alkyloxy, C_{1-6}alkyl-$S(=O)_t$, Ar^2oxy, Ar^2-$S(=O)_t$, Ar^2C_{1-6}alkyloxy, Ar^2C_{1-6}alkyl-$S(=O)_t$, Het-oxy, Het-$S(=O)_t$,HetC_{1-6}alkyloxy, HetC_{1-6}alkyl-$S(=O)_t$, carboxyl, C_{1-6}alkyloxycarbonyl and $-C(=Z)Ar^2$;

in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C_{1-6}alkyl or halogen and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C_{1-6}alkyl or halogen and R^{2b} is hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydrogen, C_{1-6}alkyl, Ar^2C_{1-6}alkyl, (Ar^2)(hydroxy) C_{1-6}alkyl, Het-C_{1-6}alkyl, hydroxyC_{1-6}alkyl, mono- and di-(C_{1-6}alkyloxy)C_{1-6}alkyl, (hydroxyC_{1-6}alkyl)oxyC_{1-6}alkyl, Ar^1C_{1-6}alkyloxy-C_{1-6}alkyl, dihydroxyC_{1-6}alkyl, (C_{1-6}alkyloxy)(hydroxy)C_{1-6}alkyl, (Ar^1C_{1-6}alkyloxy)(hydroxy) C_{1-6}alkyl, Ar^1oxy-C_{1-6}alkyl, (Ar^1oxy)(hydroxy)-C_{1-6}alkyl, aminoC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)amino-C_{1-6}alkyl, carboxyl- C_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, C_{1-6}alkylcarbonylC_{1-6}alkyl, $(C_{1-4}alkyloxy)_2$-P(=O)-C_{1-6}alkyl, $(C_{1-4}alkyloxy)_2$P(=O)-O-C_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^2carbonyl, Het-carbonyl, Ar^2C_{1-6}alkylcarbonyl, Het-C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, aminosulfonyl, mono- and di(C_{1-6}alkyl)aminosulfonyl, Ar^2sulfonyl, Ar^2C_{1-6}alkylsulfonyl, Ar^2, Het, Het-sulfonyl, HetC_{1-6}alkylsulfonyl;

R^{5a} and R^{5b} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5a} and R^{5b} taken together may form a bivalent radical of formula $-(CH_2)_s$- wherein s is 4 or 5;

R^{5c} and R^{5d} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5c} and R^{5d} taken together may form a bivalent radical of formula $-(CH_2)_s-$, wherein s is 4 or 5;

R^{6a} is hydrogen, C_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^1carbonyl, Ar^1C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, Ar^1sulfonyl, Ar^1C_{1-6}alkylsulfonyl, C_{1-6}alkyloxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-6}alkyl, (carboxyl)-C_{1-6}alkyl, (C_{1-6}alkyloxycarbonyl)-C_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, Het, Het-C_{1-6}alkyl, Het-carbonyl, Het-sulfonyl, Het-C_{1-6}alkylcarbonyl;

R^{6b} is hydrogen, C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;

R^{6c} is C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;


Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, and C_{1-6}alkyloxy;

Ar^2 is phenyl, phenyl annelated with C_{5-7} cycloalkyl, or phenyl substituted with 1 or more, such as 2, 3, 4 or 5, substituents selected from halo, cyano, C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6} alkenyl, cyanoC_{2-6}alkenyl, R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, Ar^1, Het, R^{6b}-O-, R^{6b}-S-, R^{6c}-SO-, R^{6c}-SO_2-, R^{6b}-O-C_{1-6}alkyl-SO_2-, -N($R^{6a}R^{6b}$), polyhalo-C_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, polyhaloC_{1-6}alkylthio, R^{6c}-C(=O)-, R^{6b}-O-C(=O)-, -N($R^{6a}R^{6b}$)-C(=O)-, R^{6b}-O-C_{1-10}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, -N($R^{6a}R^{6b}$)- C_{1-6}alkyl, R^{6c}-C(=O) -C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, N($R^{6a}R^{6}$)-C(=O)-C_{1-6}alkyl, R^{6c}-C(=O)-NR^{6} -, R^{6c}-C(=O) –O-, R^{6c}-C(=O) –$NR^{6b}$$C_{1-6}$alkyl, R^{6c}-C(=O) –O-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-S(=O)$_2$-, H_2N-C(=NH)-;

Het is a heterocycle being selected from tetrahydrofuranyl, tetrahydrothienyl, pynolidinyl, pynolidinonyl, furanyl, thienyl, pynolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, piperidinyl, homopiperidinyl, piperazinyl, moφholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrirmdinyl, tetrahydroquinolinyl, quinolinyl, isoquinolinyl, benzodioxanyl, benzodioxolyl, indolinyl, indolyl, each of said heterocycle may optionally be substituted with oxo, amino, Ar^1, C_{1-4}alkyl, aminoC_{1-4}alkyl,

Ar^1C_{1-4}alkyl, mono- or di(C_{1-6}alkyl)ammoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)amino, (hydroxyC_{1-6}alkyl)amino, and optionally further with one or two C_{1-4}alkyl radicals.

47. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B15) having the structure:



or a pharmaceutically acceptable salt or stereoisomer thereof,


wherein:

R^1 is hydrogen or a C_{1-6}alkyl;

R^2 is (1) amino$(CH_2)_{2-6}$; (2) amino$(CH_2)_{1-6}$difluoromethyl$(CH_2)_{1-6}$; (3) amino$(CH_2)_{1-6}$fluoromethyl$(CH_2)_{1-6}$; (4) amino$(CH_2)_{0-6}$oxetanyl$(CH_2)_{1-6}$; (5) amino$(CH_2)_{1-6}$oxetanyl$(CH_2)_{0-6}$; or (6) pyrrolidin-3-yl, unsubstituted or 4-substituted by halogen; and

X is –O–, –S–, –S(=O) –, –S(O_2)–, –CH_2–, –CF_2– or –NH–.

48. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B16) having the structure:



or pharmaceutically acceptable salts thereof,


wherein:

R^1 is hydrogen or halogen;

R^2 is hydrogen or halogen;

R^3 is azetidinyl; C_{1-6}alkoxypyridinyl; C_{1-6}alkylsulfonyl-C_xH_{2x}-; carboxycycloalkyl; difluorocycloalkyl; 1,1-dioxo-tetrahydrothienyl; halopyridinyl; hydroxy-C_yH_{2y}-; hydroxy-

C_xH_{2x}- cycloalkyl; hydroxy-C_yH_{2y}-O-C_yH_{2y}-; hydroxycycloalkyl-C_zH_{2z}-, unsubstituted or substituted by C_{1-3}alkyl, hydroxy or hydroxy-C_xH_{2x}-; 4-hydroxypiperidin-1-yl-C_yH_{2y}-; 3-hydroxy-pyrrolidin-1- yl-C_yH_{2y}-; morpholinyl-C_yH_{2y}-; oxetanyl; oxetanyl-C_xH_{2x}-, unsubstituted or substituted by C_{1-3}alkyl; piperidinyl; oxo-piperidinyl; oxo-pyrrolidinyl; pyrrolidinyl, unsubstituted or substituted by C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, hydroxy-C_yH_{2y}-, hydroxy-C_xH_{2x}-carbonyl, amino-C_xH_{2x}-carbonyl or trifluoromethyl- C_xH_{2x}-; tetrahydrofuran-3-yl- C_zH_{2z}-; tetrahydropyranyl; trifluoromethyl- C_xH_{2x}-;



R^4 is C_{1-6}alkyl or cycloalkyl;

R^5 is hydrogen or halogen;

R^7 is hydrogen or C_{1-6}alkyl;

A^1 is -N- or -CH;

A^2 is -N-, -NO or -CH;


A^3 is -N- or -CH;

x is 1-6;

y is 2-6;

z is 0-6.

49. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B17) having the structure:



or a pharmaceutically acceptable salt thereof,

wherein:

A is aryl or heteroaryl;

R_1 is alkyl, alkoxy, haloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, said heterocyclyl is optionally substituted by one to three substituents independently selected from the group consisting of halo, hydroxyl, haloalkyl, alkoxy, alkyl, alkoxy-alkyl-,hydroxyl-alkyl-, CN, alky-NH- „; said aryl or heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halo, cyano, nitro, hydroxyl, alkyl, alkoxy, alkyl-NH-, with the proviso that when A is aryl, R_1 is not unsubstituted aryl;

R_2 is hydrogen, alkyl, alkoxy, amino, alkyl-NH-, CN, alkyl-SO_2-, or halo;

R_3 is hydrogen, alkyl, heterocyclyl, heteroaryl, heteroaryl-alkyl-, or cycloalkyl, said alkyl is optionally substituted by one substituent selected from the group consisting of NH_2-C(O)-, halo, hydroxyl, NH_2-SO_2-, alkoxy-alkyl-, heterocyclyl; aryl, heteroaryl, CN, alkyl-NH-;


R_4 is hydrogen, or alkyl; or haloalkyl;

R_3 and R_4 taken together with the nitrogen atom to which they are attached optionally form a 3- to 7-membered ring;

R_5 is hydrogen, alkyl, alkoxy, haloalkyl, or halo.

50. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B18) having the structure:

I



or a pharmaceutically acceptable salt thereof,

wherein:

a) Y^1 is N, NH or CH, Y^2 is C, Y^3 is N or $CR^{8'}$, Y^4 is N or C and Y^5 is N, $NR^{2'}$ or CR^2, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$; or

b) Y^1 is N, NH or CH, Y^2 is N or C, Y^3 is N or $CR^{8'}$, Y^4 is N or C, and Y^5 is N or $NR^{2'}$, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$; or

c) Y^1 is N, NH or CH, Y^2 is N or C, Y^3 is $CR^{8'}$, Y^4 is N or C, and Y^5 is N, $NR^{2'}$ or CR^2, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$;

the dashed bonds ---- are selected from single bonds and double bonds so as to provide an aromatic ring system;

A is $-(CR^4R^{4'})_n-$ wherein any one $CR^4R^{4'}$ of said $-(CR^4R^{4'})_n-$ may be optionally replaced with –O-, -S-, $-S(O)_p-$, NH or NR^a;

n is 3, 4, 5 or 6;

each p is 1 or 2;

Ar is a C_2-C_{20} heterocyclyl group or a C_6-C_{20} aryl group, wherein the C_2-C_{20} heterocyclyl group or the C_6-C_{20} aryl group is optionally substituted with 1 to 5 R^6;

X is $-C(R^{13})(R^{14})-$, $-N(CH_2R^{14})-$ or –NH-, or X is absent;

R^1 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-R^{11}$, $-S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

R^2 is H, CN, NO_2, halogen or $(C_1$-$C_8)$alkyl;

$R^{2'}$ is H or $(C_1$-$C_8)$alkyl;

R^3 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

$R^{3'}$ is H, $-OR^{11}$, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

each R^4 is independently H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl; and

each $R^{4'}$ is independently H, OR^{11}, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

or two R^4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p$–, –NH– or $-NR^a$–;

or two R^4 on non-adjacent carbon atoms, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p$–, –NH– or $-NR^a$–;

or two R^4 and two $R^{4'}$ on adjacent carbon atoms, when taken together, may form an optionally substituted C_6 aryl ring;

or one R^4 and one $R^{4'}$ on the same carbon atom, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p$–, –NH– or $-NR^a$–;

each R^5 is independently H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

each $R^{5'}$ is independently H, $-OR^{11}$, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

each R^6 is independently H, oxo, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclykC_1-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

or two R^6 on adjacent carbon atoms, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

or any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^3, may form a bond or a $-(CR^5R^{5'})_m-$ group wherein m is 1 or 2;

or any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^2 or $R^{2'}$ may form a bond;

R^7 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

R^8 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-

C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

$R^{8'}$ is H, -OR^{11}, -$NR^{11}R^{12}$, -$NR^{11}C(O)R^{11}$, -$NR^{11}C(O)OR^{11}$, -$NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, -SR^{11}, -$S(O)_pR^a$, -$NR^{11}S(O)_pR^a$, -$C(=O)R^{11}$, -$C(=O)OR^{11}$, -$C(=O)NR^{11}R^{12}$, -$C(=O)SR^{11}$, -$S(O)_p(OR^{11})$, -$SO_2NR^{11}R^{12}$, -$NR^{11}S(O)_p(OR^{11})$, -$NR^{11}SO_pNR^{11}R^{12}$, -$NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

each R^a is independently (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl wherein any (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl or (C_2-C_8)alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl, and wherein any aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl of R^a is optionally substituted with one or more -OH, -NH_2, CO_2H, C_2-C_{20} heterocyclyl or (C_1-C_8)alkyl;

each R^{11} or R^{12} is independently H, (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkyl(C_1-C_8)alkyl, -$C(=O)R^a$ or -$S(O)_pR^a$; or when R^{11} and R^{12} are attached to a nitrogen they may optionally be taken together with the nitrogen to which they are both attached to form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, –$S(O)_p$–, –NH–, –NR^a– or –C(O)–;


R^{13} is H or (C_1-C_8)alkyl;

R^{14} is H, (C_1-C_8)alkyl, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}S(O)_pR^a$, –$NR^{11}S(O)_p(OR^{11})$ or $NR^{11}SO_pNR^{11}R^{12}$; and

wherein each (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl of each R^1, R^2, $R^{2'}$, R^3, $R^{3'}$, R^4, $R^{4'}$, R^5, $R^{5'}$, R^6, R^7, R^8, $R^{8'}$ or R^{12} is independently, optionally substituted with one or more oxo, halogen, hydroxy, –NH_2, CN, N_3, –$N(R^a)_2$, –NHR^a, –SH, –SR^a, –$S(O)_pR^a$, –OR^a, (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, –$C(O)R^a$, –C(O)H, –$C(=O)OR^a$, –C(=O)OH, –$C(=O)N(R^a)_2$, –$C(=O)NHR^a$, –$C(=O)NH_2$, –$NHS(O)_pR^a$, –$NR^aS(O)_pR^a$, –$NHC(O)R^a$, –$NR^aC(O)R^a$, –$NHC(O)OR^a$, –$NR^aC(O)OR^a$, –$NR^aC(O)NHR^a$, –$NR^aC(O)N(R^a)_2$, –$NR^aC(O)NH_2$, –$NHC(O)NHR^a$, –$NHC(O)N(R^a)_2$, –

$NHC(O)NH_2$, =NH, =NOH, $=NOR^a$, $-NR^aS(O)_pNHR^a$, $—NR^aS(O)_pN(R^a)_2$, $—NR^aS(O)_pNH_2$, $—NHS(O)_pNHR^a$, $—NHS(O)_pN(R^a)_2$, $—NHS(O)_pNH_2$, $–OC(=O)R^a$, $–OP(O)(OH)_2$ or R^a.

51. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B19) having the structure:



I

or a salt or ester thereof,

wherein:

A is $-(C(R^4)_2)_n-$ wherein any one $C(R^4)_2$ of said $-(C(R^4)_2)_n-$ may be optionally replaced with –O–, –S–, $–S(O)_p–$, NH or NR^a;

n is 3,4, 5 or 6;

each p is 1 or 2;

Ar is a C_2-C_{20} heterocyclyl group or a C_6-C_{20} aryl group, wherein the C_2-C_{20} heterocyclyl group or the C_6-C_{20} aryl group is optionally substituted with 1, 2, 3, 4 or 5 R^6;

each R^3, R^4 or R^6 is independently H, oxo, OR^{11}, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $–C(=O)R^{11}$, $–C(=O)OR^{11}$, $–C(=O)NR^{11}R^{12}$, $–C(=O)SR^{11}$, $–S(O)_p(OR^{11})$, $–SO_2NR^{11}R^{12}$, $–NR^{11}S(O)_p(OR^{11})$, $–NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl;

or two R^4 on adjacent carbon atoms, when taken together, may optionally form a double bond between the two carbons to which they are attached or may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

or four R^4 on adjacent carbon atoms, when taken together, may optionally form an optionally substituted C_6 aryl ring;

or two R^4 on the same carbon atom, when taken together, may optionally form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, –S(O)$_p$–, –NH– or –NR^a–;


or two R^6 on adjacent carbon atoms, when taken together, may optionally form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, –S(O)$_p$–, –NH– or –NR^a–;

each R^a is independently (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl wherein any (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl or (C_2-C_8)alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl, and wherein any aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl or (C_1-C_8)alkyl;


each R^{11} or R^{12} is independently H, (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl, (C_4-C_8)carbocyclylalkyl, —C(=O)R^a, —S(O)$_p$R^a or aryl(C_1-C_8)alkyl; or R^{11} and R^{12} taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, –S(O)$_p$–, –NH–, –NR^a–;or –C(O) –; and

wherein each (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl of each R^6, R^{11} or R^{12} is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH_2, CN, N_3, N(R^a)$_2$, NHR^a, SH, SR^a, S(O)$_p$R^a, OR^a, (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, –C(O)R^a, –C(O)H, –C(=O)OR^a, –C(=O)OH, –C(=O)N(R^a)$_2$, –C(=O)NHR^a, –C(=O)NH_2, NHS(O)$_p$R^a, NR^{a}S(O)$_p$R^a, NHC(O)R^a, NR^{a}C(O)R^a, NHC(O)OR^a, NR^{a}C(O)OR^a, NR^{a}C(O)NHR^a, NR^{a}C(O)N(R^a)$_2$, NR^{a}C(O)NH_2, NHC(O)NHR^a, NHC(O)N(R^a)$_2$, NHC(O)NH_2, =NH, =NOH, =NOR^a, NR^{a}S(O)$_p$NHR^a, NR^{a}S(O)$_p$N(R^a)$_2$, NR^{a}S(O)$_p$$NH_2$, NHS(O)$_p$NHR^a, NHS(O)$_p$N(Ra)$_2$, NHS(O)$_p$$NH_2$, –OC(=O)R^a, –OP(O)$(OH)_2$ or R^a.

52. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B20) having a structure selected from:



and



a pharmaceutically acceptable salt or ester,

wherein:

A is $-(C(R^4)_2)_n-$ wherein any one $C(R^4)_2$ of said $-(C(R^4)_2)_n-$ may be optionally replaced with –O–, –S–, $-S(O)_p-$, NH or NR^a;

n is 3, 4, 5 or 6;

each p is 1 or 2;

Ar is a C_2-C_{20} heterocyclyl group or a C_6-C_{20} aryl group, wherein the C_2-C_{20} heterocyclyl group or the C_6-C_{20} aryl group is optionally substituted with 1 to 5 R^6;

X is $-C(R^{13})(R^{14})-$, $-N(CH_2R^{14})-$ or X is absent;

Y is N or CR^7;

each R^1, R^2, R^3, R^4, R^5, R^6, R^7 or R^8 is independently H, oxo, OR^{11}, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl;

two R^4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p-$, –NH– or $-NR^a-$;

four R^4 on adjacent carbon atoms, when taken together, may form an optionally substituted C_6 aryl ring;

two R^4 on the same carbon atom, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

two R^6 on adjacent carbon atoms, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^3, may form a bond or a $–(C(R^5)_2)_m–$ group wherein m is 1 or 2;

any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^2, may form a bond;

each R^a is independently $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl wherein any $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, $(C_2$-$C_8)$alkenyl or $(C_2$-$C_8)$alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl, and wherein any aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl or $(C_1$-$C_8)$alkyl;

each R^{11} or R^{12} is independently H, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl, $(C_4$-$C_8)$carbocyclylalkyl, $–C(=O)R^a$, $–S(O)_pR^a$, or aryl$(C_1$-$C_8)$alkyl; or R^{11} and R^{12} taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, $–S(O)_p–$, –NH–, $–NR^a–$ or –C(O) –;


R^{13} is H or $(C_1$-$C_8)$alkyl;

R^{14} is H, $(C_1$-$C_8)$alkyl, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}S(O)_pR^{11}$, $–NR^{11}S(O)_p(OR^{11})$ or $NR^{11}SO_pNR^{11}R^{12}$; and

wherein each $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl of each R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^{11} or R^{12} is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH_2, CN, N_3, $N(R^a)_2$, NHR^a, SH, SR^a, $S(O)_pR^a$, OR^a, $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, $–C(O)R^a$, –C(O)H, $–C(=O)OR^a$, –C(=O)OH, $–C(=O)N(R^a)_2$, $–C(=O)NHR^a$, $–C(=O)NH_2$, $NHS(O)_pR^a$, $NR^aS(O)_pR^a$, $NHC(O)R^a$, $NR^aC(O)R^a$, $NHC(O)OR^a$, $NR^aC(O)OR^a$,

$NR^aC(O)NHR^a$, $NR^aC(O)N(R^a)_2$, $NR^aC(O)NH_2$, $NHC(O)NHR^a$, $NHC(O)N(R^a)_2$, $NHC(O)NH_2$, =NH, =NOH, $=NOR^a$, $NR^aS(O)_pNHR^a$, $NR^aS(O)_pN(R^a)_2$, $NR^aS(O)_pNH_2$, $NHS(O)_pNHR^a$, $NHS(O)_pN(R^a)_2$, $NHS(O)_pNH_2$, $-OC(=O)R^a$, $-OP(O)(OH)_2$ or R^a.

53. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B21) having the structure:



(I)






wherein:

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

W is O, S, C=O, C=S, NR^{3a3}, S=O, $S(=O)_2$ or $-C(R^{1a1})(R^{1a2})-$;

V is N or CH;

E is C or N; provided that when E is N, then R^{2a1} is absent;

Z is selected from the group consisting of , , , , and ;

Y is selected from the group consisting of an optionally substituted acylalkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

--------- between X^2 and X^3 represents a single or double bond between X^2 and X^3;

wherein when ------- is a double bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is N (nitrogen) or CR^{7a1}, and X^3 is N (nitrogen) or CR^4; and when -------- is a single bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is O, NR^7, C(=O) or $C(R^{7a2})(R^{7a3})$, and X^3 is NR^4, C(=O), CR^4R^8 or $CH_2CH_2C(=O)$; or

X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O), and form a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom, with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged;

L^1 is $-C(R^{17})_2-$, $-C(R^{18})_2C(R^{18a1})_2-$, $-C(R^{18a2})=C(R^{18a3})-$ or $-C(R^{19})_2N(R^{19a1})-$;

L^2 is $-C(R^{20})_2-$, $-N(R^{21})-$, S, or O;

each L^3 is independently $-C(R^{22})_2-$, $-C(R^{23})_2C(R^{23a1})_2-$ or $-C(R^{23a2})=C(R^{23a3})-$;

provided that when L^1 is $-C(R^{19})_2N(R^{19a1})-$, then L^2 is $-C(R^{20})_2-$;

R^1 is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{1a1} and R^{1a2} are each independently hydrogen, hydroxy or an unsubstituted C_{1-4} alkyl;

R^2 and R^{2a1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl); or

R^1 and R^2, together with the atoms to which they are attached, are joined to form an optionally substituted 5-membered heterocyclic ring or an optionally substituted 6-membered heterocyclic ring, R^{2a1} is selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl);

R^{3a1}, R^{3a2} and R^{3a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^4 is selected from the group consisting of hydrogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), halo(C_{1-8} alkyl), an optionally substituted hydroxyalkyl, an optionally substituted alkoxyalkyl and cyano;

R^6, R^7, and R^{7a1} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;


R^{7a2} and R^{7a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^8 is hydrogen or optionally substituted C_{1-4} alkyl;

R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15} and R^{16} are each independently hydrogen or an unsubstituted C_{1-4} alkyl; or R^9 and R^{10}, R^{11} and R^{12}, R^{13} and R^{14}, and R^{15} and R^{16}, are each independently taken together form an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and


each R^{17}, each R^{18}, each R^{18a1}, R^{18a2}, R^{18a3}, each R^{19}, R^{19a1}, each R^{20}, R^{21}, each R^{22}, each R^{23}, each R^{23a1}, R^{23a2} and R^{23a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl.

54. The method or use of any one of Claims 1-8, wherein Compound (B) is Formula (B22) having the structure:




(I)


wherein: L is selected from the group consisting of:




(Ia),



(Ib),



(Ic) and



(Id);

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

Y is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{1a}, R^{1b}, R^{1c} and R^{1d} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;


R^{2a}, R^{2a1}, R^{2b}, R^{2b1}, R^{2c}, R^{2c1}, R^{2d} and R^{2d1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or

R^{2a1} is hydrogen, and R^{1a} and R^{2a} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl, R^{2b1} is hydrogen, and R^{1b} and R^{2b} is joined together with the atoms to which they are attached to form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl;

--------- between X^{1a} and X^{2a} represents a single or double bond between X^{1a} and X^{2a}; --------- between X^{2a} and X^{3a} represents a single or double bond between X^{2a} and X^{3a}; provided that --------- between X^{1a} and X^{2a} and --------- between X^{2a} and X^{3a} cannot be both double bonds and at least one of --------- is a double bond;

when --------- between X^{1a} and X^{2a} represents a double bond and --------- between X^{2a} and X^{3a} is a single bond, then X^{1a} is N or CR^{4a}, X^{2a} is N or CR^{5a} and X^{3a} is NR^{6a1}, C(=O) or $CR^{6a2}R^{6a3}$; and when --------- between X^{1a} and X^{2a} represents a single bond and --------- between X^{2a} and X^{3a} is a double bond, then X^{1a} is NR^{4a} or $CR^{4a2}R^{4a3}$, X^{2a} is N or CR^{5a} and X^{3a} is N or CR^{6a}; or

X^{1a}, X^{2a} and X^{3a} are each independently C, N, O or C(=O), and form a ring or ring system selected from an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl by joining X^{1a} and X^{3a} together; with the proviso that the valencies of X^{1a}, X^{2a} and X^{3a} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl, and X^{1a}, X^{2a} and X^{3a} are uncharged;

R^{3a} and R^{3a1} are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3a} and R^{3a1} cannot be both hydrogen; or R^{3a} and R^{3a1} together form =N-OR^a; or R^{3a} and R^{3a1} together

with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;


R^{4a}, R^{4a1}, R^{4a2} and R^{4a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{5a} and R^{5a1} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{6a} and R^{6a1} are each independently hydrogen, an optionally substituted C_{1-4} alkyl or an optionally substituted alkoxyalkyl;

R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

X^{1b}, X^{2b} and X^{3b} are each independently C, N, O or C(=O), and form indicates a bi-cyclic ring selected from an optionally substituted bi-cyclic heteroaryl and an optionally substituted bi-cyclic heterocyclyl by joining X^{1b} and X^{3b} together, wherein --------- between X^{1b} and X^{2b} represents a single or double bond between X^{1b} and X^{2b}; --------- between X^{2b} and X^{3b} represents a single or double bond between X^{2b} and X^{3b}; and provided that at least one of X^{1b}, X^{2b} and X^{3b} comprises a nitrogen atom and both --------- cannot be double bonds; with the proviso that the valencies of X^{1b}, X^{2b} and X^{3b} can be each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl; and X^{1b}, X^{2b} and X^{3b} are uncharged;

R^{3c} and R^{3c1} are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3c} and R^{3c1} cannot be both hydrogen; or R^{3c} and R^{3c1} together form =N-OR^c; or R^{3c} and R^{3c1} together with the atom to which they are attached can be joined to form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^a and R^c are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{4c} and R^{5c} are taken together to form an unsubstituted aryl, an unsubstituted heteroaryl or an optionally substituted heterocyclyl;

Z^c is N or CH;

m^d is 0 or 1;

ring B^d is an optionally substituted C_5 cycloalkyl;

ring B^{d1} is an optionally substituted pyridinyl; and

provided that when L is Formula (IIc), then Y is absent.

55. The method or use of any one of Claims 1-54, wherein the method comprises one Compound (B), or a pharmaceutically acceptable salt thereof.

56. The method or use of any one of Claims 1-54, wherein the method comprises two of Compound (B), or a pharmaceutically acceptable salt thereof.

57. The method or use of any one of Claims 1-56, wherein R^2 is chloro.

58. The method or use of any one of Claims 1-56, wherein R^2 is azido.


59. The method or use of any one of Claims 1-58, wherein R^3 is OH.

60. The method or use of any one of Claims 1-58, wherein R^3 is $-OC(=O)R^{A1}$.

61. The method or use of Claim 60, wherein R^{A1} is unsubstituted C_{1-8} alkyl.

62. The method or use of any one of Claims 1-58, wherein R^3 is an optionally substituted O-linked amino acid.

63. The method or use of Claim 62, wherein the optionally substituted O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.

64. The method or use of Claim 62, wherein the optionally substituted O-linked amino acid has the structure , wherein R^{C1} can be selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{C2} can be hydrogen or an optionally substituted C_{1-4} alkyl; or R^{C1} and R^{C2} can be taken together to form an optionally substituted C_{3-6} cycloalkyl.

65. The method or use of any one of Claims 1-64, wherein R^1 is hydrogen.


66. The method or use of any one of Claims 1-64, wherein R^1 is an optionally substituted acyl.


67. The method or use of Claim 66, wherein the optionally substituted acyl is $-C(=O)R^{B1}$, wherein R^{B1} is an optionally substituted C_{1-24} alkyl or an optionally substituted C_{3-6} cycloalkyl.

68. The method or use of Claim 67, wherein R^{B1} is unsubstituted C_{1-8} alkyl.


69. The method or use of any one of Claims 1-64, wherein R^1 is an optionally substituted O-linked amino acid.

70. The method or use of Claim 69, wherein the optionally substituted O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.


71. The method or use of Claim 69, wherein the optionally substituted O-linked amino acid has the structure , wherein R^{C3} can be selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{C4} can be hydrogen or an optionally substituted C_{1-4} alkyl; or R^{C3} and R^{C4} can be taken together to form an optionally substituted C_{3-6} cycloalkyl.


72. The method or use of any one of Claims 1-64, wherein R^1 is .

73. The method or use of Claim 72, wherein R^6 and R^7 are independently absent or H.


74. The method or use of Claim 72, wherein R^6 and R^7 are independently .

75. The method or use of Claim 74, wherein R^6 and R^7 are independently





or


76. The method or use of Claim 72, wherein R^6 and R^7 are independently




77. The method or use of Claim 76, wherein R^6 and R^7 are independently





78. The method or use of Claim 72, wherein one of R^6 and R^7 is , and the other of R^6 and R^7 is absent or H.





79. The method or use of any one of Claims 2-64, wherein R^1 is








80. The method or use of Claim 79, wherein m is 1.












81. The method or use of Claim 79, wherein m is 2.

82. The method or use of any one of Claims 1-56, wherein Compound (A) is selected from the group consisting of:








,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

83. The method or use of any one of Claims 1-56, wherein Compound (A) is selected from the group consisting of:






,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

84. The method or use of any one of Claims 1-56, wherein Compound (A) is selected from the group consisting of:


,

,

,

,




and




, or a pharmaceutically acceptable salt of any of the foregoing.

85. The method or use of any one of Claims 2-56, wherein Compound (A) is selected from the group consisting of:



and




, or a pharmaceutically acceptable salt of any of the foregoing.

CLAIMS



1. Use of an effective amount of a combination of Compound (A) and one or more of Compound (B), or a pharmaceutical acceptable salt of any of the foregoing, in the preparation of a medicament for ameliorating or treating a paramyxovirus virus infection wherein:

the Compound (A) has the structure:



(A),




wherein:

R^1 is selected from the group consisting of H, an optionally substituted acyl, an optionally substituted O-linked amino acid,  and ;

R^2 is chloro or azido;


R^3 is selected from the group consisting of OH, $-OC(=O)R^{A1}$ and an optionally substituted O-linked amino acid;


R^4 and R^5 are independently H or D;

R^6 and R^7 is independently absent, H, ,  and ;

R^8, R^9 and each R^{10} are independently absent or H;

R^{A1} is an optionally substituted C_{1-24} alkyl;

R^{A2} is independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl, an optionally substituted –O–aryl, an optionally substituted –O–heteroaryl, an optionally substituted –O–monocyclic heterocyclyl, 

and ;

R^{A3} is selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{C1} and R^{C2} are independently selected from the group consisting of H, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

m is 1 or 2;

s is 0, 1, 2 or 3;

t is 0 or 1; and

Z^1 is O or S;

one or more of Compound (B) is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing; and

the paramyxovirus virus infection is selected from the group consisting of a respiratory syncytial virus infection, a parainfluenza virus infection and a metapneumovirus infection.

2. The use of Claim 1, wherein the paramyxovirus virus infection is a respiratory syncytial virus infection.

3. The use of Claim 2, wherein the RSV is Type A.

4. The use of Claim 2, wherein the RSV is Type B.

5. The use of Claim 1, wherein the paramyxovirus virus infection is a parainfluenza virus infection.

6. The use of Claim 1, wherein the paramyxovirus virus infection is a metapneumovirus infection.

7. The use of any one of Claims 1-6, wherein one or more of Compound (B) is an anti-RSV antibody.

8. The use of Claim 7, wherein the anti-RSV antibody is selected from the group consisting of

RSV-IGIV (RespiGam®)

palivizumab (Synagis®, a chimeric humanized IgG monoclonal antibody) and

motavizumab (MEDI-524, humanized monoclonal antibody).

9. The use of any one of Claims 1-6, wherein one or more of Compound (B) is a fusion protein inhibitor.

10. The use of Claim 9, wherein the fusion protein inhibitor is selected from the group consisting of

1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one (BMS-433771),

4,4"-bis-{4,6-bis-[3-(bis-carbamoylmethyl-sulfamoyl)-phenylamino]-(1,3,5)triazin-2-ylamino}-biphenyl-2,2"-disulfonic-acid (RFI-641),

4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazine-2-ylamino]-biphenyl-2,2'-disulfonic acid, disodium salt (CL387626),

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]-6-methyl-3-pyridinol (JNJ-2408068),

2-[[6-[[[2-(3-Hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol (TMC-353121),

5,5′-bis[1-(((5-amino-1H-tetrazolyl)imino)methyl)]2,2′,4″-methylidynetrisphenol (VP-14637, MDT-637),

N-(2-hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide (P13),

2-((2-((1-(2-aminoethyl)piperidin-4-yl)amino)-4-methyl-1H-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol (R170591),

1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane (C15),

(R)-9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydro-1H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5(9bH)-one (BTA9981),

[2,2-bis(docosyloxy-oxymethyl)propyl-5-acetaoamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium-oxysulfonyl)-D-glycero-D-galacto-2-nonulopyranosid]onate (MBX-300),

BTA-C286,

N-(2-((S)-2-(5-((S)-3-aminopyrrolidin-1-yl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)-4-chlorophenyl)methanesulfonamide (GS-5806),

an anti-RSV nanobody and

a peptide fusion inhibitor,

or a pharmaceutically acceptable salt of any of the foregoing.

11. The use of Claim 10, wherein peptide fusion inhibitor is selected from the group consisting of:

a peptide having the sequence DEFDASISQVNEKINQSLAFIRKSDELL (T-67), and

a peptide having the sequence FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST (T-118).

12. The use of any one of Claims 1-6, wherein one or more of Compound (B) is an N-protein inhibitor.

13. The use of Claim 12, wherein the N-protein inhibitor is selected from the group consisting of (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (RSV-604), STP-92 (siRNA delivered through nanoparticle based delivery systems, Sirnaomics) and iKT-041 (Inhibikase), or a pharmaceutically acceptable salt thereof.

14. The use of any one of Claims 1-6, wherein one or more of Compound (B) is a RSV polymerase inhibitor.

15. The use of Claim 14, wherein the RSV polymerase inhibitor is selected from the group consisting of

6-{4-[(biphenyl-2-ylcarbonyl)amino]benzoyl}-N-cyclopropyl-5,6-dihydro-4H-thieno[3,2-d][1]benzazepine-2-carboxamide (YM-53403),

N-cyclopropyl-5-(4-(2-(pyrrolidin-1-yl)benzamido)benzoyl)-5,6,7,10-tetrahydrobenzo[b]cyclopenta[d]azepine-9-carboxamide,

6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide,

4-amino-8-(3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl)-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-1H-imidazo[4,5-h]-isoquinoline-7,9(6H,8H)-dione and

6-(4-(2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)nicotinamido)benzoyl)-N-cyclopropyl-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide (AZ27),

or a pharmaceutically acceptable salt of any of the foregoing.

16. The use of any one of Claims 1-6, wherein one or more of Compound (B) is an IMPDH inhibitor.

17. The use of Claim 16, wherein the IMPDH inhibitor is selected from the group consisting of

ribavirin,

5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR),

4-hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide (pyrazofurin),

1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide (Taribavirin, viramidine),

1,3,4-thiadiazol-2-ylcyanamide (LY253963),

tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (VX-497),

(4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid (Mycophenolic acid) and

2-morpholin-4-ylethyl-(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate (Mycophenolate Mofetil),

or a pharmaceutically acceptable salt of any of the foregoing.

18. The use of any one of Claims 1-6, wherein one or more of Compound (B) is an interferon.

19. The use of Claim 18, wherein the interferon is a pegylated interferon.

20. The use of any one of Claims 18-19, wherein the interferon is a Type 1 interferon.

21. The use of Claim 20, wherein the Type 1 interferon is an alpha-interferon (IFN-α).

22. The use of Claim 21, wherein the IFN-α is selected from the group consisting of Pegylated interferon-alpha-2a (PEGASYS®), Pegylated interferon-alpha-2b (PEG-INTRON®) and interferon alfacon-1 (INFERGEN®).

23. The use of any one of Claims 18-19, wherein the Type 1 interferon is a beta-interferon (IFN-β).

24. The use of any one of Claims 18-19, wherein the interferon is a Type 2 interferon.

25. The use of any one of Claims 18-19, wherein the interferon is a Type 3 interferon.

26. The use of Claim 25, wherein the Type 3 interferon is a lambda-interferon (IFN-λ).

27. The use of Claim 26, wherein the IFN-λ is pegylated interferon lambda.

28. The use of any one of Claims 1-6, wherein one or more of Compound (B) is an other compound that inhibits the RSV virus.

29. The use of Claim 28, wherein the other compound is selected from the group consisting of

a double stranded RNA oligonucleotide,

5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide (leflumomide),

N-(2-chloro-4-methylphenyl)-2-((1-(4-methoxyphenyl)-1H-benzo[d]imidazol-2-yl)thio)propanamide (JMN3-003),

Medi-559,

Medi-534,

Medi-557,

an intratracheal formulation of recombinant human CC10 (CG-100),


high titer, human immunoglobulin (RI-001, ADMA Biologics Inc.) and

a non-neutralizing mAb against the G protein (mAb 131-2G),

or a pharmaceutically acceptable salt of any of the foregoing.


30. The use of Claim 29, wherein the double stranded RNA oligonucleotide is ALN-RSV01 or ALN-RSV02.

31. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B1) having the structure:




or a stereoisomeric form thereof, wherein


Het is a heterocycle having formula (b), (c), (d) or (e)




(b)



(c)



(d)



(e)

each X independently is C or N; provided that at least one X is N;

R^{1b} is present when Het has formula (b) and X is C; each R^{1b} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1b} is absent when the X to which it is bound is N;

R^{2b} is $-(CR^8R^9)_m-R^{10b}$;

each R^6 is independently selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$ and $CONHSO_2CH_3$;

each R^7 is independently selected from the group consisting of OH, C_1-C_6 alkyloxy, NH_2, $NHSO_2N(C_1\text{-}C_6\text{ alkyl})_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1\text{-}C_6\text{ alkyl})$, $NHSO_2(C_3\text{-}C_7\text{ cycloalkyl})$ and $N(C_1\text{-}C_6\text{ alkyl})_2$;

each R^8 and R^9 are independently chosen from the group consisting of H, C_1-C_{10} alkyl and C_3-C_7 cycloalkyl; or R^8 and R^9 taken together form a 4 to 6 membered aliphatic ring that optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10b} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, O-Benzyl, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$, and a 4 to 6 membered saturated ring containing one oxygen atom;

m is an integer from 2 to 6;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{12} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{12} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{1c} is present when Het has formula (c);

each R^{1c} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^{7c})$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$;

R^{3c} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy and $CO(R^{7c})$;

R^{2c} is $-(CR^8R^9)_m-R^{10c}$;

R^{7c} is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), $N(C_1$-C_6 alkyl)$_2$, NR^8R^9 and NR^9R^{10c};

R^{10c} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{1d} is present when Het has formula (d) and X is C; each R^{1d} is selected independently from the group consisting of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1d} is absent when the X to which it is bound is N;

R^{3d} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, and $CO(R^7)$;

R^{2d} is $-(CR^8R^9)_m\text{-}R^{10d}$;

R^{10d} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR_9, $OCOR^8$,$NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

each Y independently is C or N;

R^{1e} is present when Het has formula (e) and Y is C; each R^{1e} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1e} is absent when the Y to which it is bound is N;

R^{3e} is selected from the group consisting of H, halogen, $-(CR^8R^9)_m\text{-}R^{10e}$, $C\equiv C\text{-}CH_2\text{-}R^{10e}$, $C\equiv C\text{-}R^{10e}$ and $C=C\text{-}R^{10e}$;

R^{10e} is selected from the group consisting of H, R^{11}, C_1-C_6 alkyloxy, OH, CN, F, CF_2H,CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^4 is selected from the group consisting of tert-butyl, Het^1, aryl, Het^2, $CH(CH_3)(CF_3)$, and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo C_1-C_4 alkyloxy, C_1-C_4 alkyl, OH, CN, CF_2H, CF_3, CF_30, $CONR^8R^9$, $COOR^8$,$CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$,$SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$; or C_1-C_4 alkyloxyC_1-C_4 alkyloxy;

Het^1 represents a 4 to 6 membered saturated ring containing one N atom, optionally being substituted with one or more substituents each independently selected from the group consisting

of halo, C_1-C_4 alkyloxy, SO_2R^8 , C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy; or


Het^1 represents a 4 to 6 membered saturated ring containing one O atom, substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, CF_3, $NH(C=O)(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl) and C_1-C_4 alkyl; or Het represents a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N, optionally substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^8, C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;

Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, C_1-C_4 alkyl, OH, CN, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONRV^2$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$;

Z is C or N; R^5 is present where Z is C, whereby R^5 is selected form the group consisting of hydrogen, CF_3 and halogen; R^5 is absent where Z is N;


or a pharmaceutically acceptable addition salt or a solvate thereof.

32. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B2) having the structure:



a tautomer or a stereoisomeric form thereof, wherein

Het is a heterocycle having formula (a)



(a)

R^{1a} is Br or Cl;

R^{2a} is $-(CR^{8a}R^{9a})_n-R^{10a}$;

each R^{8a} and R^{9a} are independently chosen from the group consisting of H, C_1-C_{10} alkyl and C_3-C_7 cycloalkyl; or R^{8a} and R^{9a} taken together form a 4 to 6 membered aliphatic ring; wherein the 4 to 6 membered aliphatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10a} is selected from the group consisting of H, C_1-C_6 alkyl, R^{11}, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR^{8a}SO_2R^{8a}$, $SO_2NR^{8a}R^{9a}$, $NR^{8a}SO_2C_3$-C_7 cycloalkyl, CN, $NR^{8a}R^{9a}$, COOH, $COOR^{8a}$, $CONR^{8a}R^{9a}$, $OCOC_1$-C_6 alkyl, $CONR^{8a}SO_2R^{9a}$, $CONR^{8a}SO_2NR^{8a}R^{9a}$, a 4 to 6 membered aliphatic ring and a 5 to 6 membered aromatic ring; wherein the aliphatic or aromatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

n is an integer having a value from 1 to 6;

R^5 is selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkyloxy, CN, CF_3 and halo;

R^4 is selected from the group consisting of hydrogen, tert-butyl, C_3-C_7 cycloalkyl, $CH(CH_3)(CF_3)$, C_2-C_{10} alkenyl, CH_2CF_3, SO_2CH_3, -CH_2-p-fluorophenyl, aryl, Het^1, Het^2 and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$,

$NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11a}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11a}$, and C_1-C_4 alkyl;

Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^{8a} C_1-C_4 alkylcarbonyl, C_1-C_4 alkyloxycarbonyl, CO(aryl), $COHet^2$, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $NH(C=O)(C_1$-C_4 alkyl), $(C=O)NH(C_1$-C_4 alkyl), $(C=S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;


Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$,$NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11a}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11a}$ and C_1-C_4 alkyl;

R^{11a} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{11a} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

Z is CH or N;


or a pharmaceutically acceptable addition salt or a solvate thereof.


33. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B3) having the structure:





a tautomer or a stereoisomeric form thereof, wherein

Het is a heterocycle having formula (b), (c), (d) or (e)


(b)


(c)


(d)


(e)

each X independently is C or N; provided that at least one X is N;

R^{1b} is present when Het has formula (b) and X is C; each R^{1b} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1b} is absent when the X to which it is bound is N;

R^{2b} is $-(CR^8R^9)_m\text{-}R^{10b}$;

each R^6 is independently selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$ and $CONHSO_2CH_3$; each R^7 is independently selected from the group consisting of OH, C_1-C_6 alkyloxy, NH_2, $NHSO_2N(C_1\text{-}C_6\text{ alkyl})_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1\text{-}C_6\text{ alkyl})$, $NHSO_2(C_3\text{-}C_7$ cycloalkyl) and $N(C_1\text{-}C_6\text{-alkyl})_2$;

each R^8 and R^9 are independently chosen from the group consisting of H, C_1-C_6 alkyl and C_3-C_7 cycloalkyl; or R^8 and R^9 taken together form a 4 to 6 membered aliphatic ring that optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10b} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, O-Benzyl, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$, $N(R^8)COOR^{12}$ and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

R^{12} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

or R^{12} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

m is an integer from 2 to 6;

R^{1c} is present when Het has formula (c);

each R^{1c} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^{7c})$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{alkyl})_2$;

R^{3c} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy and $CO(R^{7c})$;

R^{2c} is $-(CR^8R^9)_m\text{-}R^{10c}$;

R^{7c} is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), $N(C_1\text{-}C_6\text{-alkyl})_2$, NR^8R^9 and NR^9R^{10c};

R^{10c} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^{1d} is present when Het has formula (d) and X is C; each R^{1d} is selected independently from the group consisting of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1d} is absent when the X to which it is bound is N;

R^{3d} is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, and $CO(R^7)$;

R^{2d} is $-(CR^8R^9)_m\text{-}R^{10d}$;

R^{10d} is selected from the group consisting of H, R^{11}, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CONR^8SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

each Y independently is C or N;

R^{1e} is present when Het has formula (e) and Y is C; each R^{1e} is selected independently from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkyloxy, $N(R^6)_2$, $CO(R^7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, $B(OH)_2$ and $B(O\text{-}C_1\text{-}C_6\text{ alkyl})_2$; R^{1e} is absent when the Y to which it is bound is N;

R^{3e} is selected from the group consisting of H, halogen, $-(CR^8R^9)_m-R^{10e}$, $C\equiv C\text{-}CH_2\text{-}R^{10e}$, $C\equiv C\text{-}R^{10e}$ and $C=C\text{-}R^{10e}$;

R^{10e} is selected from the group consisting of H, R^{11}, C_1-C_6 alkyloxy, OH, CN, F, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8 and a 4 to 6 membered saturated ring containing one oxygen atom;

R^5 is selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkyloxy, CN, CF_3 and halogen;

R^4 is selected from the group consisting of hydrogen, C_3-C_7 cycloalkyl, tert-butyl, C_2-C_{10} alkenyl, CH_2CF_3, $CH(CH_3)(CF_3)$, SO_2CH_3, $-CH_2$-p-fluorophenyl, aryl, Het^1, Het^2 and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl;

aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4alkyloxy, C_1-C_4alkyl, OH, CN, CF_2H, CF_3, $CONR^8R^9$, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$ and $N(R^8)COOR^{12}$;

Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 11 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R, C_1-C_4 alkylcarbonyl, CO(aryl), $COHet^2$, C_1-C_4 alkyloxycarbonyl,


pyridinyl, CF_3, $SO_2N(C_1\text{-}C_4\ alkyl)_2$, $SO_2NH(C_1\text{-}C_4\ alkyl)$,$NH(C{=}O)(C_1\text{-}C_4\ alkyl)$, $(C{=}O)NH(C_1\text{-}C_4\ alkyl)$, $(C{=}S)NH(C_1\text{-}C_4\ alkyl)$ and $C_1\text{-}C_4$ alkyl;

Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, $C_1\text{-}C_4$ alkyloxy, $C_1\text{-}C_4$ alkyl, OH, CN, CF_2H, CF_3, CONRV, $COOR^8$, $CON(R^8)SO_2R^9$, $CON(R^8)SO_2N(R^8R^9)$, NR^8R^9, NR^8COOR^9, $OCOR^8$, $NR^8SO_2R^9$, $SO_2NR^8R^9$, SO_2R^8, $OCONR^8R^9$, $OCONR^8R^{12}$, $N(R^8)CON(R^8R^9)$ and $N(R^8)COOR^{12}$;

Z is CH or N;


or a pharmaceutically acceptable addition salt or a solvate thereof.

34. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B4) having the structure:



or a stereoisomeric form thereof, wherein

Het is a heterocycle having formula (a)



(a)

R^{1a} is Br or Cl;

R^{2a} is $-(CR^{8a}R^{9a})_n\text{-}R^{10a}$;

each R^{8a} and R^{9a} are independently chosen from the group consisting of H, $C_1\text{-}C_{10}$ alkyl and $C_3\text{-}C_7$ cycloalkyl; or R^{8a} and R^{9a} taken together form a 4 to 6 membered aliphatic ring; wherein the 4 to 6 membered aliphatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{10a} is selected from the group consisting of H, C_1-C_6 alkyl, R^{11}, OH, CF_3, CHF_2, F, Cl, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR^{8a}SO_2R^{8a}$, $SO_2NR^{8a}R^{9a}$, $NR^{8a}SO_2C_3$-C_7 cycloalkyl, CN, $NR^{8a}R^{9a}$, COOH, $COOR^{8a}$, $CONR^{8a}R^{9a}$, $OCOC_1$-C_6 alkyl, $CONR^{8a}SO_2R^{9a}$, $CONR^{8a}SO_2NR^{8a}R^{9a}$, a 4 to 6 membered aliphatic ring and a 5 to 6 membered aromatic ring; wherein the aliphatic or aromatic ring optionally contains one or more heteroatoms selected from the group consisting of N, S and O;

R^{11} is selected from the group consisting of C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, pyridinyl and pyrazolyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

n is an integer having a value from 1 to 6;

R^4 is selected from the group consisting of tert-butyl, $CH(CH_3)(CF_3)$, aryl, Het^1, Het^2 and C_3-C_7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C_1-C_4 alkyl; aryl represents phenyl or naphthalenyl; said aryl optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$, $CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11b}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11b}$, and C_1-C_4 alkyl;

Het^1 represents a monocyclic 4 to 6 membered non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 7 to 1 1 non-aromatic heterocycle containing one or two heteroatoms each independently selected from the group consisting of O, S and N; said Het^1 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, SO_2R^{8a} C_1-C_4 alkylcarbonyl, C_1-C_4 alkyloxycarbonyl, CO(aryl), $COHet^2$, pyridinyl, CF_3, $SO_2N(C_1$-C_4 alkyl$)_2$, $SO_2NH(C_1$-C_4 alkyl), $NH(C{=}O)(C_1$-C_4 alkyl), $(C{=}O)NH(C_1$-C_4 alkyl), $(C{=}S)NH(C_1$-C_4 alkyl), C_1-C_4 alkyl and C_1-C_4 alkyl substituted with one hydroxy;

Het^2 represents a monocyclic 5 to 6 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; or a bicyclic 8 to 12 membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N; said Het^2 optionally being substituted with one or more substituents each independently selected from the group consisting of halo, C_1-C_4 alkyloxy, OH, CN, CF_2H, CF_3, $CONR^{8a}R^{9a}$, $COOR^{8a}$, $CON(R^{8a})SO_2R^{9a}$,


$CON(R^{8a})SO_2N(R^{8a}R^{9a})$, $NR^{8a}R^{9a}$, $NR^{8a}COOR^{9a}$, $OCOR^{8a}$, $NR^{8a}SO_2R^{9a}$, $SO_2NR^{8a}R^{9a}$, SO_2R^{8a}, $OCONR^{8a}R^{9a}$, $OCONR^{8a}R^{11b}$, $N(R^{8a})CON(R^{8a}R^{9a})$, $N(R^{8a})COOR^{11b}$ and C_1-C_4 alkyl;

R^{11b} is selected from the group consisting of phenyl, pyridinyl and pyrazolyl; each optionally substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen; or R^{11b} is C_1-C_6 alkyl or C_3-C_7 cycloalkyl; each substituted with one or more substituents each independently selected from the group consisting of CF_3, CH_3, OCH_3, OCF_3 and halogen;

Z is C or N; R^5 is present where Z is C, whereby R^5 is selected from the group consisting of hydrogen, CF_3 and halogen; R^5 is absent where Z is N;

or a pharmaceutically acceptable addition salt or a solvate thereof.

35. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B5) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_6)_2$, $CO(R_7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$;

R_2 is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, and $CO(R_7)$;

R_3 is $-(CR_8R_9)_n\text{-}R_{10}$;

R_4 is selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, SO_2-R_8, CH_2CF_3, SO_2CH_3 or a 4 to 6 membered saturated ring containing an oxygen atom;

R_5 is present where X is C, and is selected from the group consisting of H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen; R_5 is absent where X is N;

R_6 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;


R_7 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl)$_2$, $NHSO_2NCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6 alkyl)$_2$, NR_8R_9, NR_9R_{10};

n is an integer from 2 to 6;

R_8 and R_9 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_8 and R_9 taken together form a 4 to 6 membered aliphatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

R_{10} is selected from the group consisting of H, C_1-C_6 alkyl, OH, CN, F, CF_2H, CF_3, $C(=NOH)NH_2$, $CONR_8R_9$, $COOR_8$, $CONR_8SO_2R_9$, $CON(R_8)SO_2N(R_8R_9)$, NR_8R_9, NR_8COOR_9, $OCOR_8$, $NR_8SO_2R_9$, $SO_2NR_8R_9$, SO_2NR_8 or a 4 to 6 membered saturated ring containing an oxygen atom.

36. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B6) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N; at least one X = N;

each Y independently is C or N;

R_1 is present when X = C and R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_5)_2$, $CO(R_6)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$,

$C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$; R_1 is absent when X = N;

R_2 is $-(CR_7R_8)_n\text{-}R_9$;

R_3 is selected from the group consisting of H, $C_1\text{-}C_{10}$ alkyl, $C_3\text{-}C_7$ cycloalkyl, $C_2\text{-}C_{10}$ alkenyl, $SO_2\text{-}R_7$; CH_2CF_3 or a 4 to 6 membered saturated ring containing an oxygen atom;

R_4 is present where Y is C and is selected from the group consisting of H, $C_1\text{-}C_6$ alkyl, $C_1\text{-}C_6$ cycloalkyl, $C_1\text{-}C_6$ alkoxy, $CO(R_7)$, $COO(R_7)$, CF_3 and halogen,

R_5 is selected from the group consisting of H, $C_1\text{-}C_6$ alkyl, $COOCH_3$, and $CONHSO_2CH_3$;

R_6 is selected from the group consisting of OH, $O(C_1\text{-}C_6$ alkyl), NH_2, $NHSO_2N(C_1\text{-}C_6$ alkyl$)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1\text{-}C_6$ alkyl), $NHSO_2(C_3\text{-}C_7$ cycloalkyl), and $N(C_1\text{-}C_6\text{-}$alkyl$)_2$;


R_7 and R_8 are each independently chosen from H, $C_1\text{-}C_{10}$ alkyl, $C_3\text{-}C_7$ cycloalkyl or R_7 and R_8 taken together form a 4 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group N, S, O;

R_9 is selected from the group consisting of H, R_{10}, $C_1\text{-}C_6$ alkyl, OH, CN, F, CF_2H, CF_3, $CONR_7R_8$, $COOR_7$, $CON(R_7)SO_2R_8$, $CON(R_7)SO_2N(R_7R_8)$, NR_7R_8, NR_7COOR_8, $OCOR_7$, O-Benzyl, $NR_7SO_2R_8$, SO_2 R_7R_8, SO_2R_7, $OCONR_7R_8$, $OCONR_7R_{10}$, $N(R_7)CON(R_7R_8)$, $N(R_7)COOC$; phtalimido, 2-methyl-benzothiophene(1,1)di oxide, or a 4 to 6 membered saturated ring containing an oxygen atom;

n is an integer from 2 to 6;

R_{10} is selected from the group consisting of $C_1\text{-}C_6$ alkyl, $C_3\text{-}C_7$ cycloalkyl , phenyl, pyridine or pyrazole, optionally substituted with one or more substituents selected from the group comprising CF_3, CH_3, OCH_3, OCF_3 or halogen.

37. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B7) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N with at least one X being N;

R_1 is present where X = C and R_1 selected from the group of H, OH, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, NH_2, $CO(R_7)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$;

R_2 is selected from the group consisting of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, and $CO(R_7)$;

R_3 is $-(CR_8R_9)_n\text{-}R_{10}$;

R_4 is selected from the group consisting of H, C_1-C_{10} alkyl, CH_2CF_3 C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, SO_2-R_8, or a 4 to 6 membered saturated ring containing an oxygen atom;

R_5 is present where Y is C, and is selected from the group consisting of H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen;

R_5 is absent where X is N;

R_6 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;


R_7 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl$)_2$,N HSO_2NHCH_3, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6-alkyl$)_2$;

n is an integer from 2 to 6;

R_8 and R_9 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_8 and R_9 taken together form a 4 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group N, S, O;

R_{10} is selected from the group consisting of H, C_1-C_6 alkyl, OH, CN, F, CF_2H, CF_3, $CONR_8R_9$, $COOR_8$, $CONR_8SO_2R_9$, $CON(R_8)SO_2N(R_8R_9)$, NR_8R_9, NR_8COOR_9, $OCOR_8$, $NR_8SO_2R_9$, $SO_2NR_8R_9$, SO_2R_8 or a 4 to 6 membered saturated ring containing an oxygen atom.

38. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B8) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

each Y independently is C or N;

R_1 is present when X = C and R_1 is selected from the group of H, halogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, $N(R_5)_2$, $CO(R_6)$, CH_2NH_2, CH_2OH, CN, $C(=NOH)NH_2$, $C(=NOCH_3)NH_2$, $C(=NH)NH_2$, CF_3, OCF_3, and $B(OH)_2$; $B(O\text{-}C_1\text{-}C_6$ alkyl$)_2$; R_1 is absent when X = N

R_2 is selected from the group consisting of H, halogen, $-(CR_7R_8)_n-R_9$, $C\equiv C\text{-}CH_2\text{-}R_9$ and $C\equiv C\text{-}R_9$, $C=C\text{-}R_9$;

R_3 is selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, SO_2-R_7, or a 4 to 6 membered saturated ring containing an oxygen atom;

R_4 is present where Y is C and is selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 cycloalkyl, C_1-C_6 alkoxy, $CO(R_7)$, CF_3 and halogen,

R_5 is selected from the group consisting of H, C_1-C_6 alkyl, $COOCH_3$, and $CONHSO_2CH_3$;

R_6 is selected from the group consisting of OH, $O(C_1$-C_6 alkyl), NH_2, $NHSO_2N(C_1$-C_6 alkyl$)_2$, $NHSO_2NHCH_3$, $NHSO_2(C_1$-C_6 alkyl), $NHSO_2(C_3$-C_7 cycloalkyl), and $N(C_1$-C_6-alkyl$)_2$;


R_7 and R_8 are each independently chosen from H, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl or R_7 and R_8 taken together form a 4 to 6 membered aliphatic ring that optionally contains at least one heteroatom selected from the group N, S, O;

R_9 is selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl OH, CN, F, CF_2H, CF_3, $CONR_7R_8$, $COOR_7$, $CON(R_7)SO_2R_8$, $CON(R_7)SO_2N(R_7R_8)$,

NR_7R_8, NR_7COOR_8, $OCOR_7$, $NR_7SO_2R_8$, $SO_2NR_7R_8$, SO_2R_7 or a 4 to 6 membered saturated ring containing an oxygen atom;

n is an integer from 2 to 6.

39. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B9) having the structure:



or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:

each X independently is C or N;

R_1 is H;

R_2 is selected from the group consisting of Br and Cl;

R_3 is $-(CR_6R_7)_n-R_8$;

R_4 is selected from the group consisting of H, C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, $-(CR_6R_7)_n-R_8$, $-CH_2$-p-Fluorophenyl, CH_2CF_3 and $-SO_2CH_3$;


R_5 is present where X is C, whereby each R_5 is selected, each independently, from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, and CN; R_5 is absent where X is N;

R_6 and R_7 are each independently chosen from H and C_1-C_{10} alkyl, C_3-C_7 cycloalkyl; or R_6 and R_7 taken together form a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

R_8 is selected from the group consisting of H, OH, CF_3, CHF_2, F, CI, SO_2CH_3, SO_2C_3-C_7 cycloalkyl, $NR_6SO_2R_6$, $SO_2R_6R_7$, $R_6SO_2C_3$-C_7 cycloalkyl, CN, NR_6R_7, COOH, $COOR_6$, $CONR_6R_7$, $OCOC_1$-C_6 alkyl, $CONR_6SOR_7$, CONH-R_6-SO_2R_7 , CONH-R_6-$SO_2NR_6R_7CONR_6SO_2NR_6R_7$, phtalimido or a 5 to 6 membered aliphatic or aromatic ring that optionally contains one or more heteroatoms selected from the group N, S, O;

n is an integer having a value from 1 to 6.

40. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B10) having the structure:



wherein

R^1, $R^3$and R^4 each independently represents H, C1-6 alkyl or halogen;

R^2 represents H, CN, CH_2NH_2, $CH_2NH(CH_2)_3NH_2$, C(=NH)NH_2 or C(=NOH)NH_2;


R^5 represents C1-6 alkyl; said C1-6 alkyl being optionally substituted with one or more of OR^{13}, CF_3, CN or $NR^{14}R^{15}$ wherein R^{13} represents H or C1-6 alkyl and R^{14} and R^{15} independently represent H, C1-6 alkyl or C3-7 cycloalkyl; or the group -$NR^{14}R^{15}$ together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR^{19} wherein R^{19} represents H or C1-6 alkyl;

R^6, R^7, R^8 and R^9 each independently represents CH, C-F, C-Cl, C-CF_3 or N;

R^{10} represents aryl, heteroaryl, C3-7 cycloalkyl or C1-6 alkyl; said C1-6 alkyl or C3-7 cycloalkyl being optionally substituted with one or more of aryl, C3-7 cycloalkyl, OR^{16}, SR^{16}, halogen or $NR^{17}R^{18}$, wherein R^{16} represents H or C1-6 alkyl and R^{17} and R^{18} each independently represents H, C1-6 alkyl or C3-7 cycloalkyl; or the group -$NR^{17}R^1$ together represents a 5 to 7 membered azacyclic ring optionally incorporating one heteroatom selected from O, S and NR^{20} wherein R^{20} represents H or C1-6 alkyl; and

R^{11} and R^{12} each independently represents H or C1-6 alkyl.

41. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B11) having the structure:



or racemates, isomers and/or salts thereof,

wherein:


X_1 and X_2 are independently selected from CH and N wherein at least one of X_1 and X_2 is N;

R_1 is optionally substituted and is selected from a carbocyclic, heterocyclic and aromatic ring;

R_2 is selected from C_{1-6} alkyl, haloC_{1-3}alkyl and C_{1-3}alkoxy; and

R_3 is H or an optional substituent.

42. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B12) having the structure:



or an enantiomer or a salt thereof,

wherein:

R^1 is -$(CH=CH)_{0-1}$-(C_6 or C_{10})aryl or -$(CH=CH)_{0-1}$-5-, 6-, 9- or 10- membered heteroaryl, said aryl or heteroaryl being optionally substituted with one, two or three substituents, each independently selected from: (C_{1-6})alkyl optionally substituted with amino, halo, (C_{1-6})haloalkyl, hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, nitro, azido, cyano, amino,(C_{1-6})alkylamino, di((C_{1-6})aIkyl)amino, aryl and heteroaryl;


R^2 is H, (C_{1-6})alkyl, hydroxy, halo, (C_{1-6})haloalkyl, amino, (C_{1-6})alkylamino. di((C_{1-6})alkyl)amino, or (C_{2-6})alkynyl;

R^3 is (C_6, C_{10} or C_{14})aryl or 5-, 6-, 9- or 10-membered heteroaryl, each of which being optionally substituted with one, two or three substituents, each independently selected from: (C_{1-6})alkyl, halo, (C_{1-6})haloalkyl, hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, nitro, amino, (C_{1-6})alkylamino, di((C_{1-6})alkyl)amino and COO(C_{1-6})alkyl; and

R^4 and R^5 are each independently H or (C_{1-6})alkyl; or R^4 and R^5 are linked, together with the carbon atom to which they are attached, to form a (C_{3-7})cycloalkyl group;

with the proviso that R^1 is not 2-methoxyphenyl, when R^2 is H, R^3 is 3,4-dimethoxyphenyl, R^4 is CH_3 and R^5 is CH_3.


43. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B13) having the structure:



or a salt or a stereochemically isomeric form thereof,

wherein:

R is a radical of formula



(a) (b)

Q is hydrogen or C_{1-6}alkyl optionally substituted with a heterocycle or Q is C_{1-6}alkyl substituted with both a radical -OR^4 and a heterocycle; wherein said heterocycle is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl,1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo- hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, hydroxy, carboxyl, C_{1-6} alkyloxycarbonyl, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, C_{1-6}alkylcarbonylamino, aminosulfonyl and mono- or di(C_{1-6}alkyl)aminosulfonyl;

Alk is C_{1-6}alkanediyl;

X is O or S;

$-a^1=a^2-a^3=a^4-$ is a bivalent radical of formula -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- or -CH=CH-CH=N-; wherein one of the nitrogen atoms bears the chemical bond linking radical (b) with the rest of the molecule;

R^1 is Ar or a heterocycle selected from pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, pyridopyridyl, naphthiridinyl, lH-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]- pyridinyl, imidazo[1,2-a]pyridinyl and 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; wherein each of said heterocycle may optionally be substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyloxy, (C_{1-6}alkyl-oxy)C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkyloxycarbonyl, aminocarbonyl, mono- and di- C_{1-6}alkylaminocarbonyl;

R^2 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, Ar-C_{1-6}alkyloxy-C_{1-6}alkyl, C_{3-7} cycloalkyl, cyano-C_{1-6}alkyl, Ar-C_{1-6}alkyl, Het-C_{1-6}alkyl;

R^3 is hydrogen, C_{1-6}alkyl, cyano, aminocarbonyl, polyhaloC_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;


R^4 is hydrogen or C_{1-6}alkyl;

each Ar independently is phenyl or phenyl substituted with 1 to 5, such as 1, 2, 3 or 4, substituents selected from halo, hydroxy, amino, mono- or di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylamino, C_{1-6}alkylsulfonylamino, cyano, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, phenyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkyloxy, polyhaloC_{1-6}alkyloxy, phenoxy, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, hydroxycarbonyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylcarbonyl, amino sulfonyl, mono- and di(C_{1-6}alkyl)- aminosulfonyl;

Het is a heterocycle selected from the group consisting of pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, iuranyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl and 2,3-dihydro-

1,4-dioxino-[2,3-b]pyridyl; wherein each Het may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, amino, mono- or di(C_{1-6}alkyl)amino, cyano, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkyloxy.

44. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B14) having the structure:




or a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof,

wherein:


G is a direct bond or C_{1-10}alkanediyl optionally substituted with one or more substituents independently selected from the group of substituents consisting of hydroxy, C_{1-6}alkyloxy, Ar^1 C_{1-6}alkyloxy,C_{1-6}alkylthio, Ar^1 C_{1-6}alkylthio,$HO(-CH_2-CH_2-O)_n-$, C_{1-6}alkyloxy$(-CH_2-CH_2-O)_a-$ or Ar^1 C_{1-6}alkyloxy$(-CH_2-CH_2-O)n-$;

each n independently is 1, 2, 3 or 4;


R^1 is Ar^1 or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro- furanyl, thienyl, pynolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]- pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl or a radical of formula




(c-1)





(c-2)





(c-3)


(c-4)


(c-5)


(c-6)


(c-7)


(c-8) ;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted with 1 or where possible more, such as 2, 3, 4 or 5, substituents independently selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyCi-ealkyl, Ar^1, Ar^1C_{1-6}alkyl, Ar^1C_{1-6}alkyloxy, hydroxyC_{1-6}alkyl,mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino,C_{1-6}alkyl-SO_2-NR^{5c}-, Ar^1-SO_2-NR^{5c}-, C_{1-6}alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-CH_2-CH_2-O)$_n$-, halo(-CH_2-CH_2-O)„-, C_{1-6}alkyloxy(-CH_2-CH_2-O)„-, Ar^1C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$- and mono-or di(C_{1-6}alkyl)amino(-CH_2-CH_2-O)$_n$-;

each m independently is 1 or 2;

each p independently is 1 or 2;

each t independently is 0, 1 or 2;

Q is hydrogen, amino or mono- or di(C_{1-4}alkyl)amino;

one of R^{2a} and R^{3a} is selected from halo, optionally mono- or polysubstituted C_{1-6}alkyl, optionally mono- or polysubstituted C_{2-6}alkenyl, nitro, hydroxy, Ar^2, $N(R^{4a}R^4)$, $N(R^{4a}R^{4b})$sulfonyl, $N(R^{4a}R^4)$carbonyl, C_{1-6}alkyloxy, Ar^2oxy, Ar^2C_{1-6}alkyloxy,carboxyl, C_{1-6}alkyloxycarbonyl, or -C(=Z)Ar^2; and the other one of R^{2a} and R^{3a} is hydrogen; wherein =Z is =O, =CH-C(=O) -$NR^{5a}R^{5b}$, =CH_2, =CH- C_{1-6}alkyl, =N-OH or =N-O- C_{1-6}alkyl; and the optional substituents on C_{1-6}alkyl and C_{2-6} alkenyl can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydroxy, cyano, halo, nitro, $N(R^{4a}R^{4b})$, $N(R^{4a}R^{4b})$sulfonyl, Het, Ar^2, C_{1-6}alkyloxy, C_{1-6}alkyl-$S(=O)_t$, Ar^2oxy, Ar^2-$S(=O)_t$, Ar^2C_{1-6}alkyloxy, Ar^2C_{1-6}alkyl-$S(=O)_t$, Het-oxy, Het-$S(=O)_t$,HetC_{1-6}alkyloxy, HetC_{1-6}alkyl-$S(=O)_t$, carboxyl, C_{1-6}alkyloxycarbonyl and -C(=Z)Ar^2;

in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C_{1-6}alkyl or halogen and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C_{1-6}alkyl or halogen and R^{2b} is hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydrogen, C_{1-6}alkyl, Ar^2C_{1-6}alkyl, (Ar^2)(hydroxy) C_{1-6}alkyl, Het-C_{1-6}alkyl, hydroxyC_{1-6}alkyl, mono- and di-(C_{1-6}alkyloxy)C_{1-6}alkyl, (hydroxyC_{1-6}alkyl)oxyC_{1-6}alkyl, Ar^1C_{1-6}alkyloxy-C_{1-6}alkyl, dihydroxyC_{1-6}alkyl, (C_{1-6}alkyloxy)(hydroxy)C_{1-6}alkyl, (Ar^1C_{1-6}alkyloxy)(hydroxy) C_{1-6}alkyl, Ar^1oxy-C_{1-6}alkyl, (Ar^1oxy)(hydroxy)-C_{1-6}alkyl, aminoC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)amino-C_{1-6}alkyl, carboxyl- C_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, C_{1-6}alkylcarbonylC_{1-6}alkyl, $(C_{1-4}alkyloxy)_2$-P(=O)-C_{1-6}alkyl, $(C_{1-4}alkyloxy)_2$P(=O)-O-C_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^2carbonyl, Het-carbonyl, Ar^2C_{1-6}alkylcarbonyl, Het-C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, aminosulfonyl, mono- and di(C_{1-6}alkyl)aminosulfonyl, Ar^2sulfonyl, Ar^2C_{1-6}alkylsulfonyl, Ar^2, Het, Het-sulfonyl, HetC_{1-6}alkylsulfonyl;

R^{5a} and R^{5b} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5a} and R^{5b} taken together may form a bivalent radical of formula $-(CH_2)_S-$ wherein s is 4 or 5;

R^{5c} and R^{5d} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5c} and R^{5d} taken together may form a bivalent radical of formula $-(CH_2)_S-$ wherein s is 4 or 5;

R^{6a} is hydrogen, C_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^1carbonyl, Ar^1C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, Ar^1sulfonyl, Ar^1C_{1-6}alkylsulfonyl, C_{1-6}alkyloxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-6}alkyl, (carboxyl)-C_{1-6}alkyl, (C_{1-6}alkyloxycarbonyl)-C_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, Het, Het-C_{1-6}alkyl, Het-carbonyl, Het-sulfonyl, Het-C_{1-6}alkylcarbonyl;

R^{6b} is hydrogen, C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;


R^{6c} is C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;

Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, and C_{1-6}alkyloxy;

Ar^2 is phenyl, phenyl annelated with C_{5-7} cycloalkyl, or phenyl substituted with 1 or more, such as 2, 3, 4 or 5, substituents selected from halo, cyano, C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6} alkenyl, cyanoC_{2-6}alkenyl, R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, Ar^1, Het, R^{6b}-O-, R^{6b}-S-, R^{6c}-SO-, R^{6c}-SO_2-, R^{6b}-O-C_{1-6}alkyl-SO_2-, -N($R^{6a}R^{6b}$), polyhalo-C_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, ρolyhaloC_{1-6}alkylthio, R^{6c}-C(=O)-, R^{6b}-O-C(=O)-, -N($R^{6a}R^{6b}$)-C(=O)-, R^{6b}-O-C_{1-10}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, -N($R^{6a}R^{6b}$)- C_{1-6}alkyl, R^{6c}-C(=O) -C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, N($R^{6a}R^6$)-C(=O)-C_{1-6}alkyl, R^{6c}-C(=O)-NR^6 -, R^{6c}-C(=O) –O-, R^{6c}-C(=O) –$NR^{6b}C_{1-6}$alkyl, R^{6c}-C(=O) –O-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-S(=O)$_2$-, H_2N-C(=NH)-;

Het is a heterocycle being selected from tetrahydrofuranyl, tetrahydrothienyl, pynolidinyl, pynolidinonyl, furanyl, thienyl, pynolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, piperidinyl, homopiperidinyl, piperazinyl, moφholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrirmdinyl, tetrahydroquinolinyl, quinolinyl, isoquinolinyl, benzodioxanyl, benzodioxolyl, indolinyl, indolyl, each of said heterocycle may optionally be substituted with oxo, amino, Ar^1, C_{1-4}alkyl, aminoC_{1-4}alkyl, Ar^1C_{1-4}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)amino, (hydroxyC_{1-6}alkyl)amino, and optionally further with one or two C_{1-4}alkyl radicals.

45. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B15) having the structure:



or a pharmaceutically acceptable salt or stereoisomer thereof,


wherein:

R^1 is hydrogen or a C_{1-6}alkyl;

R^2 is (1) amino$(CH_2)_{2-6}$; (2) amino$(CH_2)_{1-6}$difluoromethyl$(CH_2)_{1-6}$; (3) amino$(CH_2)_{1-6}$fluoromethyl$(CH_2)_{1-6}$; (4) amino$(CH_2)_{0-6}$oxetanyl$(CH_2)_{1-6}$; (5) amino$(CH_2)_{1-6}$oxetanyl$(CH_2)_{0-6}$; or (6) pyrrolidin-3-yl, unsubstituted or 4-substituted by halogen; and

X is –O–, –S–, –S(=O) –, –S(O_2) –, –CH_2–, –CF_2– or –NH–.

46. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B16) having the structure:




or pharmaceutically acceptable salts thereof,

wherein:

R^1 is hydrogen or halogen;

R^2 is hydrogen or halogen;

R^3 is azetidinyl; C_{1-6}alkoxypyridinyl; C_{1-6}alkylsulfonyl-C_xH_{2x}-; carboxycycloalkyl; difluorocycloalkyl; 1,1-dioxo-tetrahydrothienyl; halopyridinyl; hydroxy-C_yH_{2y}-; hydroxy-C_xH_{2x}-cycloalkyl; hydroxy-C_yH_{2y}-O-C_yH_{2y}-; hydroxycycloalkyl-C_zH_{2z}-, unsubstituted or substituted by C_{1-3}alkyl, hydroxy or hydroxy-C_xH_{2x}-; 4-hydroxypiperidin-1-yl-C_yH_{2y}-; 3-hydroxy-pyrrolidin-1-yl-C_yH_{2y}-; morpholinyl-C_yH_{2y}-; oxetanyl; oxetanyl-C_xH_{2x}-, unsubstituted or substituted by C_{1-3}alkyl; piperidinyl; oxo-piperidinyl; oxo-pyrrolidinyl; pyrrolidinyl, unsubstituted or substituted by C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, hydroxy- C_yH_{2y}-, hydroxy-C_xH_{2x}-carbonyl, amino-C_xH_{2x}-carbonyl or trifluoromethyl- C_xH_{2x}-; tetrahydrofuran-3-yl- C_zH_{2z}-; tetrahydropyranyl; trifluoromethyl- C_xH_{2x}-;



R^4 is C_{1-6}alkyl or cycloalkyl;

R^5 is hydrogen or halogen;

R^7 is hydrogen or C_{1-6}alkyl;

A^1 is -N- or -CH;

A^2 is -N-, -NO or -CH;


A^3 is -N- or -CH;

x is 1-6;

y is 2-6;

z is 0-6.

47. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B17) having the structure:



or a pharmaceutically acceptable salt thereof,

wherein:

A is aryl or heteroaryl;

R_1 is alkyl, alkoxy, haloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, said heterocyclyl is optionally substituted by one to three substituents independently selected from the group consisting of halo, hydroxyl, haloalkyl, alkoxy, alkyl, alkoxy-alkyl-,hydroxyl-alkyl-, CN, alky-NH- „; said aryl or heteroaryl is optionally substituted by one to three substituents independently selected from the group consisting of halo, cyano, nitro, hydroxyl, alkyl, alkoxy, alkyl-NH-, with the proviso that when A is aryl, R_1 is not unsubstituted aryl;

R_2 is hydrogen, alkyl, alkoxy, amino, alkyl-NH-, CN, alkyl-SO_2-, or halo;

R_3 is hydrogen, alkyl, heterocyclyl, heteroaryl, heteroaryl-alkyl-, or cycloalkyl, said alkyl is optionally substituted by one substituent selected from the group consisting of NH_2-C(O)-, halo, hydroxyl, NH_2-SO_2-, alkoxy-alkyl-, heterocyclyl; aryl, heteroaryl, CN, alkyl-NH-;


R_4 is hydrogen, or alkyl; or haloalkyl;

R_3 and R_4 taken together with the nitrogen atom to which they are attached optionally form a 3- to 7-membered ring;

R_5 is hydrogen, alkyl, alkoxy, haloalkyl, or halo.

48. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B18) having the structure:

I



or a pharmaceutically acceptable salt thereof,

wherein:

a) Y^1 is N, NH or CH, Y^2 is C, Y^3 is N or $CR^{8'}$, Y^4 is N or C and Y^5 is N, $NR^{2'}$ or CR^2, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$; or

b) Y^1 is N, NH or CH, Y^2 is N or C, Y^3 is N or $CR^{8'}$, Y^4 is N or C, and Y^5 is N or $NR^{2'}$, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$; or

c) Y^1 is N, NH or CH, Y^2 is N or C, Y^3 is $CR^{8'}$, Y^4 is N or C, and Y^5 is N, $NR^{2'}$ or CR^2, wherein at least two of Y^1, Y^2, Y^3, Y^4 and Y^5 are independently N, NH or $NR^{2'}$;

the dashed bonds ---- are selected from single bonds and double bonds so as to provide an aromatic ring system;

A is $-(CR^4R^{4'})_n-$ wherein any one $CR^4R^{4'}$ of said $-(CR^4R^{4'})_n-$ may be optionally replaced with –O-, -S-, $-S(O)_p-$, NH or NR^a;

n is 3, 4, 5 or 6;

each p is 1 or 2;

Ar is a C_2-C_{20} heterocyclyl group or a C_6-C_{20} aryl group, wherein the C_2-C_{20} heterocyclyl group or the C_6-C_{20} aryl group is optionally substituted with 1 to 5 R^6;

X is $-C(R^{13})(R^{14})-$, $-N(CH_2R^{14})-$ or –NH-, or X is absent;

R^1 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-R^{11}$, $-S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

R^2 is H, CN, NO_2, halogen or $(C_1$-$C_8)$alkyl;

$R^{2'}$ is H or $(C_1$-$C_8)$alkyl;

R^3 is H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

$R^{3'}$ is H, $-OR^{11}$, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl$(C_1$-$C_8)$alkyl, $(C_3$-$C_7)$cycloalkyl or $(C_3$-$C_7)$cycloalkyl$(C_1$-$C_8)$alkyl;

each R^4 is independently H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, -

$NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $C_2\text{-}C_{20}$ heterocyclyl$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_7)$cycloalkyl or $(C_3\text{-}C_7)$cycloalkyl$(C_1\text{-}C_8)$alkyl; and

each $R^{4'}$ is independently H, OR^{11}, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $C_2\text{-}C_{20}$ heterocyclyl$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_7)$cycloalkyl or $(C_3\text{-}C_7)$cycloalkyl$(C_1\text{-}C_8)$alkyl;

or two R^4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a $(C_3\text{-}C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3\text{-}C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_P–$, –NH– or $–NR^a–$;

or two R^4 on non-adjacent carbon atoms, when taken together, may form a $(C_3\text{-}C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3\text{-}C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_P–$, –NH– or $–NR^a–$;

or two R^4 and two $R^{4'}$ on adjacent carbon atoms, when taken together, may form an optionally substituted C_6 aryl ring;

or one R^4 and one $R^{4'}$ on the same carbon atom, when taken together, may form a $(C_3\text{-}C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3\text{-}C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_P–$, –NH– or $–NR^a–$;

each R^5 is independently H, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $C_2\text{-}C_{20}$ heterocyclyl$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_7)$cycloalkyl or $(C_3\text{-}C_7)$cycloalkyl$(C_1\text{-}C_8)$alkyl;

each $R^{5'}$ is independently H, $-OR^{11}$, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $C_2\text{-}C_{20}$ heterocyclyl$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_7)$cycloalkyl or $(C_3\text{-}C_7)$cycloalkyl$(C_1\text{-}C_8)$alkyl;

each R^6 is independently H, oxo, $-OR^{11}$, $-NR^{11}R^{12}$, $-NR^{11}C(O)R^{11}$, $-NR^{11}C(O)OR^{11}$, $-NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, $-SR^{11}$, $-S(O)_pR^a$, $-NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $-NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}$

C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclykC_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

or two R^6 on adjacent carbon atoms, when taken together, may form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, –S(O)$_P$–, –NH– or –NR^a–;

or any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^3, may form a bond or a -($CR^5R^{5'}$)$_m$- group wherein m is 1 or 2;

or any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^2 or $R^{2'}$ may form a bond;

R^7 is H, -OR^{11}, -$NR^{11}R^{12}$, -$NR^{11}C(O)R^{11}$, -$NR^{11}C(O)OR^{11}$, -$NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, -SR^{11}, -$S(O)_pR^a$, -$NR^{11}S(O)_pR^a$, -$C(=O)R^{11}$, -$C(=O)OR^{11}$, -$C(=O)NR^{11}R^{12}$, -$C(=O)SR^{11}$, -$S(O)_p(OR^{11})$, -$SO_2NR^{11}R^{12}$, -$NR^{11}S(O)_p(OR^{11})$, -$NR^{11}SO_pNR^{11}R^{12}$, -$NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

R^8 is H, -OR^{11}, -$NR^{11}R^{12}$, -$NR^{11}C(O)R^{11}$, -$NR^{11}C(O)OR^{11}$, -$NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, -SR^{11}, -$S(O)_pR^a$, -$NR^{11}S(O)_pR^a$, -$C(=O)R^{11}$, -$C(=O)OR^{11}$, -$C(=O)NR^{11}R^{12}$, -$C(=O)SR^{11}$, -$S(O)_p(OR^{11})$, -$SO_2NR^{11}R^{12}$, -$NR^{11}S(O)_p(OR^{11})$, -$NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

$R^{8'}$ is H, -OR^{11}, -$NR^{11}R^{12}$, -$NR^{11}C(O)R^{11}$, -$NR^{11}C(O)OR^{11}$, -$NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, -SR^{11}, -$S(O)_pR^a$, -$NR^{11}S(O)_pR^a$, -$C(=O)R^{11}$, -$C(=O)OR^{11}$, -$C(=O)NR^{11}R^{12}$, -$C(=O)SR^{11}$, -$S(O)_p(OR^{11})$, -$SO_2NR^{11}R^{12}$, -$NR^{11}S(O)_p(OR^{11})$, -$NR^{11}SO_pNR^{11}R^{12}$, -$NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl;

each R^a is independently (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl wherein any (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl or (C_2-C_8)alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H,

C_2-C_{20} heterocyclyl, and wherein any aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl of R^a is optionally substituted with one or more -OH, -NH_2, CO_2H, C_2-C_{20} heterocyclyl or (C_1-C_8)alkyl;

each R^{11} or R^{12} is independently H, (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl, (C_3-C_7)cycloalkyl(C_1-C_8)alkyl, -$C(=O)R^a$ or -$S(O)_pR^a$; or when R^{11} and R^{12} are attached to a nitrogen they may optionally be taken together with the nitrogen to which they are both attached to form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, –$S(O)_p$–, –NH–, –NR^a– or –C(O)–;


R^{13} is H or (C_1-C_8)alkyl;

R^{14} is H, (C_1-C_8)alkyl, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}S(O)_pR^a$, –$NR^{11}S(O)_p(OR^{11})$ or $NR^{11}SO_pNR^{11}R^{12}$; and

wherein each (C_1-C_8)alkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, C_2-C_{20} heterocyclyl(C_1-C_8)alkyl, (C_3-C_7)cycloalkyl or (C_3-C_7)cycloalkyl(C_1-C_8)alkyl of each R^1, R^2, $R^{2'}$, R^3, $R^{3'}$, R^4, $R^{4'}$, R^5, $R^{5'}$, R^6, R^7, R^8, $R^{8'}$ or R^{12} is independently, optionally substituted with one or more oxo, halogen, hydroxy, –NH_2, CN, N_3, –$N(R^a)_2$, –NHR^a, –SH, –SR^a, –$S(O)_pR^a$, –OR^a, (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, –$C(O)R^a$, –C(O)H, –$C(=O)OR^a$, –C(=O)OH, –$C(=O)N(R^a)_2$, –$C(=O)NHR^a$, –$C(=O)NH_2$, –$NHS(O)_pR^a$, –$NR^aS(O)_pR^a$, –$NHC(O)R^a$, –$NR^aC(O)R^a$, –$NHC(O)OR^a$, –$NR^aC(O)OR^a$, –$NR^aC(O)NHR^a$, –$NR^aC(O)N(R^a)_2$, –$NR^aC(O)NH_2$, –$NHC(O)NHR^a$, –$NHC(O)N(R^a)_2$, –$NHC(O)NH_2$, =NH, =NOH, =NOR^a, –$NR^aS(O)_pNHR^a$, —$NR^aS(O)_pN(R^a)_2$, —$NR^aS(O)_pNH_2$, —$NHS(O)_pNHR^a$, —$NHS(O)_pN(R^a)_2$, —$NHS(O)_pNH_2$, –$OC(=O)R^a$, –$OP(O)(OH)_2$ or R^a.

49. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B19) having the structure:

I



or a salt or ester thereof,

wherein:

A is $-(C(R^4)_2)_n-$ wherein any one $C(R^4)_2$ of said $-(C(R^4)_2)_n-$ may be optionally replaced with –O–, –S–, $–S(O)_p–$, NH or NR^a;

n is 3,4, 5 or 6;

each p is 1 or 2;

Ar is a C_2-C_{20} heterocyclyl group or a C_6-C_{20} aryl group, wherein the C_2-C_{20} heterocyclyl group or the C_6-C_{20} aryl group is optionally substituted with 1, 2, 3, 4 or 5 R^6;

each R^3, R^4 or R^6 is independently H, oxo, OR^{11}, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $–C(=O)R^{11}$, $–C(=O)OR^{11}$, $–C(=O)NR^{11}R^{12}$, $–C(=O)SR^{11}$, $–S(O)_p(OR^{11})$, $–SO_2NR^{11}R^{12}$, $–NR^{11}S(O)_p(OR^{11})$, $–NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, ($C_1$-$C_8$)alkyl, ($C_2$-$C_8$)alkenyl, ($C_2$-$C_8$)alkynyl, aryl($C_1$-$C_8$)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl;

or two R^4 on adjacent carbon atoms, when taken together, may optionally form a double bond between the two carbons to which they are attached or may form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

or four R^4 on adjacent carbon atoms, when taken together, may optionally form an optionally substituted C_6 aryl ring;

or two R^4 on the same carbon atom, when taken together, may optionally form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;


or two R^6 on adjacent carbon atoms, when taken together, may optionally form a (C_3-C_7)cycloalkyl ring wherein one carbon atom of said (C_3-C_7)cycloalkyl ring may be optionally replaced by –O–, –S–, $–S(O)_p–$, –NH– or $–NR^a–$;

each R^a is independently (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl, (C_2-C_8)alkynyl, aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl wherein any (C_1-C_8)alkyl, (C_1-C_8)haloalkyl, (C_2-C_8)alkenyl or (C_2-C_8)alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl, and wherein any aryl(C_1-C_8)alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, (C_3-C_7)cycloalkyl or (C_4-C_8)carbocyclylalkyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl or (C_1-C_8)alkyl;


each R^{11} or R^{12} is independently H, $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $(C_3\text{-}C_7)$cycloalkyl, $(C_4\text{-}C_8)$carbocyclylalkyl, —$C(=O)R^a$, —$S(O)_pR^a$ or aryl$(C_1\text{-}C_8)$alkyl; or R^{11} and R^{12} taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, –$S(O)_p$–, –NH–, –NR^a–;or –C(O) –; and

wherein each $(C_1\text{-}C_8)$alkyl, $(C_2\text{-}C_8)$alkenyl, $(C_2\text{-}C_8)$alkynyl, aryl$(C_1\text{-}C_8)$alkyl, $C_6\text{-}C_{20}$ aryl, $C_2\text{-}C_{20}$ heterocyclyl, $(C_3\text{-}C_7)$cycloalkyl or $(C_4\text{-}C_8)$carbocyclylalkyl of each R^6, R^{11} or R^{12} is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH_2, CN, N_3, $N(R^a)_2$, NHR^a, SH, SR^a, $S(O)_pR^a$, OR^a, $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$haloalkyl, $–C(O)R^a$, –C(O)H, –$C(=O)OR^a$, –C(=O)OH, –$C(=O)N(R^a)_2$, –$C(=O)NHR^a$, –$C(=O)NH_2$, $NHS(O)_pR^a$, $NR^aS(O)_pR^a$, $NHC(O)R^a$, $NR^aC(O)R^a$, $NHC(O)OR^a$, $NR^aC(O)OR^a$, $NR^aC(O)NHR^a$, $NR^aC(O)N(R^a)_2$, $NR^aC(O)NH_2$, $NHC(O)NHR^a$, $NHC(O)N(R^a)_2$, $NHC(O)NH_2$, =NH, =NOH, $=NOR^a$, $NR^aS(O)_pNHR^a$, $NR^aS(O)_pN(R^a)_2$, $NR^aS(O)_pNH_2$, $NHS(O)_pNHR^a$, $NHS(O)_pN(Ra)_2$, $NHS(O)_pNH_2$, $–OC(=O)R^a$, $–OP(O)(OH)_2$ or R^a.

50. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B20) having a structure selected from:



and



a pharmaceutically acceptable salt or ester,

wherein:

A is $–(C(R^4)_2)_n–$ wherein any one $C(R^4)_2$ of said $–(C(R^4)_2)_n$- may be optionally replaced with –O–, –S–, $–S(O)_p–$, NH or NR^a;

n is 3, 4, 5 or 6;

each p is 1 or 2;

Ar is a $C_2\text{-}C_{20}$ heterocyclyl group or a $C_6\text{-}C_{20}$ aryl group, wherein the $C_2\text{-}C_{20}$ heterocyclyl group or the $C_6\text{-}C_{20}$ aryl group is optionally substituted with 1 to 5 R^6;

X is $-C(R^{13})(R^{14})-$, $-N(CH_2R^{14})-$ or X is absent;

Y is N or CR^7;

each R^1, R^2, R^3, R^4, R^5, R^6, R^7 or R^8 is independently H, oxo, OR^{11}, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, N_3, CN, NO_2, SR^{11}, $S(O)_pR^a$, $NR^{11}S(O)_pR^a$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-C(=O)SR^{11}$, $-S(O)_p(OR^{11})$, $-SO_2NR^{11}R^{12}$, $-NR^{11}S(O)_p(OR^{11})$, $-NR^{11}SO_pNR^{11}R^{12}$, $NR^{11}C(=NR^{11})NR^{11}R^{12}$, halogen, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl;

two R^4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p-$, –NH– or $-NR^a-$;

four R^4 on adjacent carbon atoms, when taken together, may form an optionally substituted C_6 aryl ring;

two R^4 on the same carbon atom, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p-$, –NH– or $-NR^a-$;

two R^6 on adjacent carbon atoms, when taken together, may form a $(C_3$-$C_7)$cycloalkyl ring wherein one carbon atom of said $(C_3$-$C_7)$cycloalkyl ring may be optionally replaced by –O–, –S–, $-S(O)_p-$, –NH– or $-NR^a-$;

any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^3, may form a bond or a $-(C(R^5)_2)_m-$ group wherein m is 1 or 2;

any R^6 adjacent to the obligate carbonyl group of said Ar, when taken together with R^2, may form a bond;

each R^a is independently $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl wherein any $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, $(C_2$-$C_8)$alkenyl or $(C_2$-$C_8)$alkynyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl, and wherein any aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl of R^a is optionally substituted with one or more OH, NH_2, CO_2H, C_2-C_{20} heterocyclyl or $(C_1$-$C_8)$alkyl;


each R^{11} or R^{12} is independently H, $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl, $(C_4$-$C_8)$carbocyclylalkyl, –$C(=O)R^a$, –$S(O)_pR^a$, or aryl$(C_1$-$C_8)$alkyl; or R^{11} and R^{12} taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with –O–, –S–, –$S(O)_p$–, –NH–, –NR^a– or –C(O) –;

R^{13} is H or $(C_1$-$C_8)$alkyl;

R^{14} is H, $(C_1$-$C_8)$alkyl, $NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}S(O)_pR^a$, –$NR^{11}S(O)_p(OR^{11})$ or $NR^{11}SO_pNR^{11}R^{12}$; and

wherein each $(C_1$-$C_8)$alkyl, $(C_2$-$C_8)$alkenyl, $(C_2$-$C_8)$alkynyl, aryl$(C_1$-$C_8)$alkyl, C_6-C_{20} aryl, C_2-C_{20} heterocyclyl, $(C_3$-$C_7)$cycloalkyl or $(C_4$-$C_8)$carbocyclylalkyl of each R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^{11} or R^{12} is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH_2, CN, N_3, $N(R^a)_2$, NHR^a, SH, SR^a, $S(O)_pR^a$, OR^a, $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$haloalkyl, –$C(O)R^a$, –C(O)H, –$C(=O)OR^a$, –C(=O)OH, –$C(=O)N(R^a)_2$, –$C(=O)NHR^a$, –$C(=O)NH_2$, $NHS(O)_pR^a$, $NR^aS(O)_pR^a$, $NHC(O)R^a$, $NR^aC(O)R^a$, $NHC(O)OR^a$, $NR^aC(O)OR^a$, $NR^aC(O)NHR^a$, $NR^aC(O)N(R^a)_2$, $NR^aC(O)NH_2$, $NHC(O)NHR^a$, $NHC(O)N(R^a)_2$, $NHC(O)NH_2$, =NH, =NOH, $=NOR^a$, $NR^aS(O)_pNHR^a$, $NR^aS(O)_pN(R^a)_2$, $NR^aS(O)_pNH_2$, $NHS(O)_pNHR^a$, $NHS(O)_pN(R^a)_2$, $NHS(O)_pNH_2$, –$OC(=O)R^a$, –$OP(O)(OH)_2$ or R^a.

51. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B21) having the structure:



(I)






wherein:

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl$(C_{1\text{-}2}$ alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

W is O, S, C=O, C=S, NR^{3a3}, S=O, $S(=O)_2$ or $–C(R^{1a1})(R^{1a2})–$;

V is N or CH;

E is C or N; provided that when E is N, then R^{2a1} is absent;

Z is selected from the group consisting of , , , , and ;

Y is selected from the group consisting of an optionally substituted acylalkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

-------- between X^2 and X^3 represents a single or double bond between X^2 and X^3;

wherein when ------ is a double bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is N (nitrogen) or CR^{7a1}, and X^3 is N (nitrogen) or CR^4; and when -------- is a single bond, then X^1 is NR^{3a1} or $CR^{3a2}R^6$, X^2 is O, NR^7, C(=O) or $C(R^{7a2})(R^{7a3})$, and X^3 is NR^4, C(=O), CR^4R^8 or $CH_2CH_2C(=O)$; or

X^1, X^2 and X^3 are each independently C (carbon), N (nitrogen), O (oxygen) or C(=O), and form a mono-cyclic ring selected from the group consisting of an optionally substituted mono-cyclic heteroaryl and an optionally substituted mono-cyclic heterocyclyl by joining X^1 and X^3 together; and provided that at least one of X^1, X^2 and X^3 comprises a nitrogen atom, with the proviso that the valencies of X^1, X^2 and X^3 are satisfied with a substituent selected from the group consisting of hydrogen and an optionally substituted C_{1-4} alkyl; and X^1, X^2 and X^3 are uncharged;

L^1 is $-C(R^{17})_2-$, $-C(R^{18})_2C(R^{18a1})_2-$, $-C(R^{18a2})=C(R^{18a3})-$ or $-C(R^{19})_2N(R^{19a1})-$;

L^2 is $-C(R^{20})_2-$, $-N(R^{21})-$, S, or O;

each L^3 is independently $-C(R^{22})_2-$, $-C(R^{23})_2C(R^{23a1})_2-$ or $-C(R^{23a2})=C(R^{23a3})-$;

provided that when L^1 is $-C(R^{19})_2N(R^{19a1})-$, then L^2 is $-C(R^{20})_2-$;

R^1 is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{1a1} and R^{1a2} are each independently hydrogen, hydroxy or an unsubstituted C_{1-4} alkyl;

R^2 and R^{2a1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally

substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl); or

R^1 and R^2, together with the atoms to which they are attached, are joined to form an optionally substituted 5-membered heterocyclic ring or an optionally substituted 6-membered heterocyclic ring, R^{2a1} is selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, hydroxy, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl);

R^{3a1}, R^{3a2} and R^{3a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^4 is selected from the group consisting of hydrogen, an optionally substituted C_{1-8} alkyl, an optionally substituted C_{2-8} alkenyl, an optionally substituted C_{2-8} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted C_{3-6} cycloalkyl(C_{1-6} alkyl), an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), halo(C_{1-8} alkyl), an optionally substituted hydroxyalkyl, an optionally substituted alkoxyalkyl and cyano;

R^6, R^7, and R^{7a1} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{7a2} and R^{7a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^8 is hydrogen or optionally substituted C_{1-4} alkyl;





R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15} and R^{16} are each independently hydrogen or an unsubstituted C_{1-4} alkyl; or R^9 and R^{10}, R^{11} and R^{12}, R^{13} and R^{14}, and R^{15} and R^{16}, are each independently taken together form an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and

each R^{17}, each R^{18}, each R^{18a1}, R^{18a2}, R^{18a3}, each R^{19}, R^{19a1}, each R^{20}, R^{21}, each R^{22}, each R^{23}, each R^{23a1}, R^{23a2} and R^{23a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl.

52. The use of any one of Claims 1-6, wherein Compound (B) is Formula (B22) having the structure:

$$A—L—Y \quad (I)$$

wherein: L is selected from the group consisting of:


(Ia),

(Ib),

(Ic) and

(Id);

A is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-2} alkyl), an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

Y is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{1a}, R^{1b}, R^{1c} and R^{1d} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{2a}, R^{2a1}, R^{2b}, R^{2b1}, R^{2c}, R^{2c1}, R^{2d} and R^{2d1} are each independently selected from the group consisting of hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heterocyclyl(C_{1-6} alkyl), an alkoxyalkyl, an aminoalkyl, a hydroxyalkyl and hydroxy; or


R^{2a1} is hydrogen, and R^{1a} and R^{2a} together with the atoms to which they are attached form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl, R^{2b1} is hydrogen, and R^{1b} and R^{2b} together with the atoms to which they are attached form an optionally substituted 5 membered heterocyclyl or an optionally substituted 6 membered heterocyclyl;

-------- between X^{1a} and X^{2a} represents a single or double bond between X^{1a} and X^{2a}; ------ between X^{2a} and X^{3a} represents a single or double bond between X^{2a} and X^{3a}; provided that ------ between X^{1a} and X^{2a} and -------- between X^{2a} and X^{3a} cannot be both double bonds and at least one of -------- is a double bond;

when -------- between X^{1a} and X^{2a} represents a double bond and -------- between X^{2a} and X^{3a} is a single bond, then X^{1a} is N or CR^{4a1}, X^{2a} is N or CR^{5a} and X^{3a} is NR^{6a1}, C(=O) or

$CR^{6a2}R^{6a3}$; and when -------- between X^{1a} and X^{2a} represents a single bond and -------- between X^{2a} and X^{3a} is a double bond, then X^{1a} is NR^{4a} or $CR^{4a2}R^{4a3}$, X^{2a} is N or CR^{5a} and X^{3a} is N or CR^{6a}; or

X^{1a}, X^{2a} and X^{3a} are each independently C, N, O or C(=O), and form a ring or ring system selected from an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl by joining X^{1a} and X^{3a} together; with the proviso that the valencies of X^{1a}, X^{2a} and X^{3a} are each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl, and X^{1a}, X^{2a} and X^{3a} are uncharged;

R^{3a} and R^{3a1} are each independently selected from the group consisting of hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3a} and R^{3a1} cannot be both hydrogen; or R^{3a} and R^{3a1} together form =N-OR^a; or R^{3a} and R^{3a1} together with the atom to which they are attached form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^{4a}, R^{4a1}, R^{4a2} and R^{4a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;


R^{5a} is hydrogen or an unsubstituted C_{1-4} alkyl;

R^{6a} and R^{6a1} are each independently hydrogen, an optionally substituted C_{1-4} alkyl or an optionally substituted alkoxyalkyl;

R^{6a2} and R^{6a3} are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

X^{1b}, X^{2b} and X^{3b} are each independently C, N, O or C(=O), and form a bi-cyclic ring selected from an optionally substituted bi-cyclic heteroaryl and an optionally substituted bi-cyclic heterocyclyl by joining X^{1b} and X^{3b} together, wherein -------- between X^{1b} and X^{2b} represents a single or double bond between X^{1b} and X^{2b}; -------- between X^{2b} and X^{3b} represents a single or double bond between X^{2b} and X^{3b}; and provided that at least one of X^{1b}, X^{2b} and X^{3b} comprises a nitrogen atom and both -------- cannot be double bonds; with the proviso that the

valencies of X^{1b}, X^{2b} and X^{3b} are each independently satisfied with a substituent selected from hydrogen and an optionally substituted C_{1-4} alkyl; and X^{1b}, X^{2b} and X^{3b} are uncharged;

R^{3c} and R^{3c1} are each independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{2-4} alkenyl, an optionally substituted C_{2-4} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{1-4} alkoxy, -O-carboxy, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, CHF_2, CF_3 and , provided that R^{3c} and R^{3c1} cannot be both hydrogen; or R^{3c} and R^{3c1} together form =N-OR^c; or R^{3c} and R^{3c1} together with the atom to which they are attached form an optionally substituted 3 membered ring, an optionally substituted 4 membered ring, an optionally substituted 5 membered ring or an optionally substituted 6 membered ring;

R^a and R^c are each independently hydrogen or an unsubstituted C_{1-4} alkyl;

R^{4c} and R^{5c} are taken together to form an unsubstituted aryl, an unsubstituted heteroaryl or an optionally substituted heterocyclyl;

Z^c is N or CH;

m^d is 0 or 1;

ring B^d is an optionally substituted C_5 cycloalkyl;

ring B^{d1} is an optionally substituted pyridinyl; and

provided that when L is Formula (Ic), then Y is absent.

53. The use of any one of Claims 1-52, wherein the use comprises one Compound (B), or a pharmaceutically acceptable salt thereof.

54. The use of any one of Claims 1-52, wherein the use comprises two of Compound (B), or a pharmaceutically acceptable salt thereof.

55. The use of any one of Claims 1-54, wherein R^2 is chloro.

56. The use of any one of Claims 1-54, wherein R^2 is azido.


57. The use of any one of Claims 1-56, wherein R^3 is OH.

58. The use of any one of Claims 1-56, wherein R^3 is $-OC(=O)R^{A1}$.

59. The use of Claim 58, wherein R^{A1} is unsubstituted C_{1-8} alkyl.

60. The use of any one of Claims 1-56, wherein R^3 is an optionally substituted O-linked amino acid.

61. The use of Claim 60, wherein the optionally substituted O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.

62. The use of Claim 61, wherein the optionally substituted O-linked amino acid has the structure , wherein R^{C1} can be selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{C2} can be hydrogen or an optionally substituted C_{1-4} alkyl; or R^{C1} and R^{C2} can be taken together to form an optionally substituted C_{3-6} cycloalkyl.

63. The use of any one of Claims 1-62, wherein R^1 is hydrogen.


64. The use of any one of Claims 1-62, wherein R^1 is an optionally substituted acyl.


65. The use of Claim 64, wherein the optionally substituted acyl is $-C(=O)R^{B1}$, wherein R^{B1} is an optionally substituted C_{1-24} alkyl or an optionally substituted C_{3-6} cycloalkyl.

66. The use of Claim 65, wherein R^{B1} is unsubstituted C_{1-8} alkyl.




67. The use of any one of Claims 1-62, wherein R^1 is an optionally substituted O-linked amino acid.




68. The use of Claim 67, wherein the optionally substituted O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.


69. The use of Claim 67, wherein the optionally substituted O-linked amino acid has the structure , wherein R^{C3} can be selected from hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{C4} can be hydrogen or an optionally substituted C_{1-4} alkyl; or R^{C3} and R^{C4} can be taken together to form an optionally substituted C_{3-6} cycloalkyl.

70. The use of any one of Claims 1-62, wherein R^1 is .

71. The use of Claim 70, wherein R^6 and R^7 are independently absent or H.

72. The use of Claim 70, wherein R^6 and R^7 are independently  or ; or wherein one of R^6 and R^7 is , and the other of R^6 and R^7 is absent or H.

73. The use of Claim 72, wherein R^6 and R^7 are independently ,  or .







74. The use of any one of Claims 2-62, wherein R^1 is






75. The use of Claim 74, wherein m is 1.












76. The use of Claim 74, wherein m is 2.







77. The use of any one of Claims 1-54, wherein Compound (A) is selected from the group consisting of:


,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.





78. The use of any one of Claims 1-54, wherein Compound (A) is selected from the group consisting of:



,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

79. The use of any one of Claims 1-54, wherein Compound (A) is selected from the group consisting of:


,

,

,

,




and




, or a pharmaceutically acceptable salt of any of the foregoing.

80. The use of any one of Claims 2-54, wherein Compound (A) is selected from the group consisting of:



and



, or a pharmaceutically acceptable salt of any of the foregoing.